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Abstract
Fourteen expanded trinucleotide loci have been found to cause neurological diseases 
including Huntington’s Disease, myotonic dystrophy type 1 and spinocerebellar ataxia.
The repeat sequence and allele sizes vary between each locus, and the flanking DNA is 
assumed to play a significant role in repeat instability. The aim of this project was to 
characterise the behaviour and mutability of two trinucleotide repeat loci with the same 
repeat sequence, but with different flanking DNA sequences. Comparing the mutation rates 
and average length changes of these loci in the male germline demonstrated a clear effect of 
the influence of the flanking sequence. The ERDA1 locus has low %GC content in the 
flanking sequence and displays a low mutation rate, even for large length alleles, whereas 
CTG18.1 has a relatively high %GC content and demonstrates an increased mutation rate 
and average length change for similarly sized alleles. Utilising the sensitive SP-PCR 
technique gives a clear insight into how the CTG18.1 locus has responded dramatically to 
defects in mismatch repair, both in MMR deficient cell lines and HNPCC tissues, and 
possibly in an ovarian tumour. This investigation has also revealed a possible dominant 
negative mutation in the hMLHl gene which maintains its influence on an expanded 
CTG18.1 allele in two generations of a HNPCC family. In conclusion, we have 
successfully characterised the behaviour of two trinucleotide repeat loci which highlights 
the significant effect of flanking DNA sequence on the stability of triplet repeats.
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Chapter 1
Introduction
1.1 Triplet Repeats
Short tandem repeats (STRs) represent a common class of eukaryotic repetitive DNA which 
can range from 1-6 bp and vary in their sequence. Mononucleotide repeats are frequently 
made up of adenosine and dinucleotide repeats used for linkage analysis are often (CA)n. 
Trinucleotide repeats have become the focus of much attention over the last ten years as an 
increasing number of neurological diseases are attributed to expansions of this type of repeat 
from the normal range for that locus. These trinucleotides can differ in their sequence, the 
purity of this sequence, their location in respect to a gene, the range of alleles detected and 
repeat behaviour in somatic and germline tissues. Fourteen expandable trinucleotide repeat 
diseases have been identified in humans so far, known as FRAXA (Fu et a l, 1991), SBMA (La 
Spada et a l, 1991), DM-1 (Fu et al., 1991, Aslanidis et al., 1992, Brook et al., 1992, Buxton et 
al., 1992, Harley et al., 1992, Mahadevan et al., 1992), FRAXE (Flynn et al., 1993), HD (The 
Huntington's Disease Collaborative Research Group, 1993), SCA1 (Orr et al., 1993), DRPLA 
(Koide et al., 1994), MJD/SCA3 (Kawaguchi et al., 1994), Friedreich’s ataxia (Campuzano et 
a l, 1996), SCA2 (Imbert et al., 1996, Pulst et al., 1996, Sanpei et al., 1996), SCA6 (Zhuchenko 
et al., 1997), SCA7 (David et al., 1997), SCA8 (Koob et al., 1999) and SCA12 (Holmes et al., 
1999). Expandable trinucleotides at the FRA16A (Nancarrow et al., 1994), FRAXF (Parrish et 
al., 1994) and FRA11B (Jones et al., 1994) loci do not directly cause diseases but in the case 
of FRA11B can lead to a chromosome deletion involving 1 lq23 that results in Jacobsen 
syndrome. GDNF (Grimm et al., 1998), PABP2 (Brais et al., 1998) and TBP (Imbert et al.,
1994) have been investigated in patients with neurological disorders and although expanded 
alleles of 7-13 repeats at PABP2 (Brais et al., 1998) and 60 repeats at TBP (Koide et al.,
1999) have been detected, no direct association has been found with disease. Other loci such 
as CTG18.1 (Breschel etal., 1997), ERDA1 (Nakamoto etal., 1997, Ikeuchi et al., 1998), and 
CAGR1 (Margolis et al., 1996) also have expandable repeats which are not associated with a 
disease. Diseases such as autosomal dominant pure spastic paraplegia (Nielsen et a l, 1997, 
Benson et al., 1998), bipolar affective disorder and schizophrenia (Lindblad et a l, 1995,
Morris et al., 1995, Vincent et al, 1996, Oruc et al, 1997, Burgess et a l, 1998, Vincent et al,
1998), are also hypothesised to be caused by as yet unidentified expanded trinucleotide repeat 
sequences.
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Genes containing trinucleotide repeats are present in normal individuals, with the number of 
repeats ranging from several to approximately 40. The presence of an expanded allele with a 
trinucleotide repeat size exceeding the normal range leads to expression of disease phenotypes 
(Table 1.1). Anticipation is a feature of triplet repeat diseases, whereby repeat size increases 
in transmission are associated with an earlier onset of the disease accompanied with more 
severe symptoms. The repeat can be in the 5’ UTR, 3’ UTR, coding or non-coding regions 
of a gene (Figure 1.1) and have the potential to expand to greater than 1,000 repeats at loci 
such as DM-1, CTG18.1, FRAXA, FRAXF, FRA11B, FRA16A and Friedreich’s ataxia.
Hence alleles such as the DM-1 repeat can be characterised as either normal (<40 repeats), 
premutation (40-50 repeats), protomutation (50-80 repeats), adult onset (>100 repeats) or 
congenital (>700 repeats).
1.2 Mosaicism of triplet repeats
1.2.1 Somatic Mosaicism
Somatic mosaicism is defined as any observed differences in the cells of the same tissue or 
the tissues of the same individual. Somatic mosaicism became an issue after observations of 
differences in repeat sizes of trinucleotide repeats between tissues (Anvret et al., 1993, Jansen 
et al., 1994, Thornton etal., 1994, Massari etal., 1995, Kinoshita etal., 1996) and an 
increasing heterogenous smear in blood over time at the DM-1 locus (Wong et al., 1995).
PCR or Southern blots of the expanded repeats demonstrated larger alleles in muscle (Anvret 
et al., 1993, Thornton et al., 1994, Massari et a l, 1995, Kinoshita et al., 1996), brain 
(Thornton etal., 1994), testes (Thornton etal., 1994), liver (Thornton et a l, 1994, Kinoshita et 
al., 1996), lung (Kinoshita et a l, 1996), pancreas (Kinoshita et a l, 1996), kidney (Kinoshita et 
al, 1996), heart (Kinoshita et al, 1996) and sperm (Massari et a l, 1995) compared to 
leukocytes. However there were no size increases in lymph node, spleen and thymus 
(Kinoshita et a l, 1996) and an apparent reduction in repeat length in the cerebellum, although 
this could be the progenitor allele length and hence all other tissues have expansions 
(Kinoshita et a l, 1996). It also became apparent that other triplet repeats demonstrated 
somatic mosaicism, though not to the same extent as DM-1. DRPLA, (Ito et a l, 1998, Tanaka 
et a l, 1999), HD (Telenius et al, 1994, De Rooij et a l, 1995), SCA1 (Cancel et a l, 1998) and 
MJD/SCA3 (Cancel et a l, 1998, Ito et al, 1998), also have smaller repeats in the cerebellum 
though no somatic mosaicism could be found in different brain regions of SCA6 patients 
(Ishikawa et al., 1999). SCA1 and FRAXA alleles sized from blood contract with increasing 
progenitor repeat size (Momet et al, 1996, Koefoed et al, 1998, Nolin et a l, 1999), whereas 
SCA7 alleles have increasing numbers of extra bands with increasing allele size (Gouw et al,
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1998), and longer MJD/SCA3 alleles have been detected in liver and colon (Ito et a l, 1998). 
Analysis with large quantities of DNA indicated no somatic mosaicism in the brains of HD 
patients (MacDonald et a l, 1993, Zuhlke et a l, 1993), although extra bands were detected in 
other studies (Telenius et al, 1994, De Rooij et al, 1995) and differences have now been 
detected using fluorescent PCR in the caudate nucleus, frontal cortex and the white matter, 
compared to leukocytes (Tanaka et al, 1999).
Using a technique known as Small Pool PCR (SP-PCR), it is now possible to understand 
why larger smears are evident in the muscle of DM-1 patients over time (Wong et a l, 1995) 
or how larger repeat bands are consistently observed in testes or sperm, irrelevant of the 
disease (MacDonald et a l, 1993, Telenius et al, 1994, Massari et a l, 1995, Kinoshita et al, 
1996, Takiyama et al, 1997, De Michele et a l, 1998, Tanaka et a l, 1999). Multiple aliquots 
of a known number of molecules of DNA undergo PCR across the repeat of interest so that 
the smear observed in tissues can be resolved into the component allele population (Monckton 
et a l, 1995). Using SP-PCR it has become clear that there is a tissue-specific, age and 
progenitor allele size effect on the repeat behaviour. SP-PCR on the DM-1 and SCA7 repeats 
demonstrates that there is a defined lower boundary of repeat contraction in muscle, blood and 
buccal cells which is presumed to be the progenitor allele (Monckton et a l, 1995, Martorell et 
al, 1998, Monckton et a l, 1999). Over time, the repeat is heavily biased toward expansions 
which explains the larger smear detected with large quantities of DNA in muscle. SP-PCR 
showed that a FRAXA 55 repeat is relatively stable in blood (Momet et a l, 1996) and single 
molecule PCR confirmed an increasing contraction rate with increasing allele size (Nolin et 
al, 1999).
1.2.2 Germline Mosaicism
Anticipation within disease families suggests that triplet repeats are also unstable in the 
germline. There is a clear parental effect on the transmission of the DM-1, DRPLA, SCA7 
and SCA8 repeats and the age of the transmitting parent at conception can also contribute to an 
increased progenitor allele size. To directly observe male germline instability of repeats, 
single sperm analysis can be approached in two ways. Single sperm can be physically 
separated, lysed and PCR (either fluorescent or radioactive) performed on the haploid 
genomic DNA, or DNA extracted from a sperm sample can be diluted to effectively single 
sperm level and PCR performed, with or without fluorescently labelled primers. Fluorescent 
PCR products can be separated on polyacrylamide sequencing gels and analysed by ALF 
Fragment Manager or GeneScan software to compare the mutation rates of single sperm to 
somatic DNA (frequently blood DNA) from the same individual. Normal (<50 repeats) and
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expanded (>50 repeats) alleles have been analysed from affected patients at the DRPLA 
(Takiyama et a l, 1999), FRAXA (Kunst et al, 1997, Nolin et a l, 1999), HD (Leeflang et a l, 
1995, Chong et a l, 1997, Leeflang et al, 1999), MJD/SCA3 (Takiyama et a l, 1997), SBMA 
(Zhang et a l, 1994), and SCA1 (Koefoed et a l, 1998) loci. There is a large amount of 
variability in the male germline between the different diseases and given the similarity in 
sequence, the flanking DNA is presumed to play a large part in instability (Brock et a l, 1999). 
Limited single molecule data is available for the majority of the triplet diseases, the most 
comprehensively covered being HD (Leeflang et al, 1995, Chong et a l, 1997, Leeflang et a l, 
1999), followed by MJD/SCA3 (Takiyama et a l, 1997). The distribution of the expanded 
alleles broadens with increasing allele size (Leeflang et al, 1999), with an increasing 
frequency of expansions relative to contractions in HD (Leeflang et a l, 1995, Chong et a l, 
1997, Leeflang et a l, 1999), and the opposite effect is seen in MJD/SCA3 (Takiyama et a l,
1997). HD alleles can reach a 90% mutation rate by 38-40 repeats (Leeflang et a l, 1995, 
Leeflang et a l, 1999) and although there is a lack of alleles to compare with in this range, 50 
SCA1 repeats, 60-62 DRPLA repeats, 74-75 MJD/SCA3 repeats and 100 FRAXA repeats have 
mutation rates of 75% (Koefoed et al, 1998), 96-98% (Takiyama et a l, 1999), 88-91% 
(Takiyama et a l, 1997) and 55% respectively, although interruptions are frequent in the 
FRAXA repeat which decreases the mutation rates of equivalently sized alleles (Nolin et a l, 
1999). Dramatic reversions have been detected in the male germline, both in DM-1 
(Monckton et a l, 1995) and Friedreich’s ataxia (De Michele et a l, 1998).
Therefore single molecule analysis can confirm observations in disease pedigrees, although it 
is not presently feasible to detect repeat behaviour in the female germline. Variations are 
observed between alleles of the same size from different individuals (Zhang et a l, 1994, 
Leeflang et al, 1995, Chong et al, 1997, Leeflang et a l, 1999) and though some can be 
attributed to age of the individual or the transmitting parent (De Michele et a l, 1998), others 
cannot (Leeflang et a l, 1999). Unequal transmission of the expanded allele versus the normal 
allele has also been seen in SCA1 and MJD/SCA3 disease pedigrees, resulting in the 
phenomenon of segregation distortion in the offspring (Riess et a l, 1997). The mechanism 
of meiotic drive has been hypothesised to contribute to segregation distortion and evidence 
from DRPLA and MJD/SC A3 suggests this may be a factor in the male germline (Ikeuchi et 
a l, 1996) although no evidence was found for FRAXA or FRAXE in either sex (Teague et al,
1998). Detailed work concerning meiotic drive and segregation distortion has been carried 
out at the DM-1 locus with conflicting results. Early work suggesting segregation distortion 
of alleles >19 repeats from the male germline in normal pedigrees (Carey et a l, 1994, 
Gennarelli et a l, 1994) was reanalysed and no significant evidence for meiotic drive in males 
was found (Hurst et a l, 1995). Single sperm analysis from three heterozygotes with alleles <
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and >19 repeats found no difference in the number of smaller versus larger alleles (Leeflang 
e ta l,  1996).
1.3 Locus CTG18.1
Locus CTG18.1 was first identified in 1997 while searching for a candidate for Bipolar 
Affective Disorder (BPAD). Due to reports of anticipation and linkage to chromosome 18, a 
human genomic chromosome 18 library was screened with a (CAG)15 repeat probe and a 1.6 
kbp insert was identified containing a (CTG)24 flanked immediately 3’ by a non-polymorphic 
(CTC)13 repeat (Breschel et al., 1997). PCR was carried out with primers flanking the repeat 
on 56 unrelated individuals from 15 Centre d’Etude du Polymorphisme Humain (CEPH) 
pedigrees and 48 BPAD families which contained at least one treated BPAD patient and at 
least two affected first degree relatives. A subset of the BPAD families showed linkage to 
chromosome 18q21. CTG18.1 demonstrated a heterozygosity of 84% with highly 
polymorphic allele lengths. The CTG18.1 locus was mapped to 18q21.1 by two-point linkage 
analysis in 48 families ascertained for BPAD. When comparing allele sizes between affected 
and unaffected at the CTG18.1 locus, there was no evidence for linkage between CTG18.1 
and BPAD. In six BPAD families moderately enlarged (CTG)>86 alleles were evident. PCR 
detected alleles ranging from (CTG)10 to (CTG)250. Alleles between 10 and 37 repeats were 
inherited stably in 261 out of 262 transmissions, whereas moderately enlarged (53-250 
repeats) alleles demonstrated instability in 18 transmissions observed. Enlarged alleles at the 
CTG18.1 locus segregated randomly with respect to BPAD. Sequencing across the enlarged 
repeats confirmed that the expansion derived from the CTG repeat and that the CTC repeat 
remained stable. Further research indicated very enlarged alleles (800-2100 repeats) at the 
CTG 18.1 locus that could only be detected by genomic Southern blots in three BPAD 
individuals and a Danish pedigree. However, these very enlarged alleles also segregated 
independently of the BPAD phenotype.
In the same study it was reported that some CEPH families had expanded Repeat Expansion 
Detection (RED) products mapped to 18q (Schalling e ta l, 1993). CEPH families 1334,
1344 and 1420 were amplified by PCR at locus CTG 18.1. Families 1344 and 1420 inherited 
enlarged alleles in a mendelian manner and 1334 had normal stable alleles. This illustrated 
that the RED technique (Figure 1.2) may have detected the expanded alleles at the CTG18.1 
locus in families 1344 and 1420, but that another locus may be responsible for the RED 
bands detected in family 1334. Typing at the CTG18.1 locus in individuals from BPAD 
families found an expansion frequency (>40 repeats) of 3% (Verheyen et al., 1999),
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confirming earlier findings (Breschel et al, 1997). Alleles greater than 100 repeats were not 
accurately sized and so could not be commented on in terms of instability in transmission. 
However, a contraction of an approximately 133 repeat allele to 87 repeats in maternal 
transmission was observed.
The CTG18.1 locus has also been investigated in cases of familial Parkinson’s disease (PD) 
in combination with the RED method (Schraen-Maschke et a l, 1999). Expanded CAG/CTG 
RED products in some PD patients (21.9%) led to screening at the CTG18.1 locus and two 
expanded alleles of 65 and 67 repeats were detected in a patient and control, respectively. 
CTG18.1 was discounted of involvement in the PD phenotype.
1.4 Locus ERDA1
A second expandable CAG/CTG repeat not associated with a disease was found on 
chromosome 17q21.3 (Nakamoto et al, 1997). As with CTG18.1, this repeat had been 
detected by the RED method and subsequently cloned. The DNA fragment was named 
ERDA1 (expanded repeat domain CAG/CTG 1) and repeats ranged from 10-30 and 55-92 in 
healthy Japanese and Caucasian individuals, demonstrating a bimodal distribution. The 
frequencies of the larger ERDA1 alleles are again higher than in DM. 26% of Japanese and 
8% of Caucasian alleles had greater than 51 repeats, with alleles from 66-87 repeats stably 
transmitted from parent to offspring. The larger alleles possess an A—>C polymorphism 
immediately 3’ to the CTG repeat. An independent study also directly compared allele 
distributions in Japanese and French individuals, dividing the bimodal distribution into short 
and long alleles and naming the locus Dirl. Japanese alleles ranged from 10-26 and 52-92 
repeats and French alleles ranged from 10-25 and 50-78 repeats with heterozygosities of 85% 
and 82% respectively (Ikeuchi et a l, 1998). The study agreed with the previous study that 
large alleles are more prevalent in the Japanese (38.2%) than in French (17.2%). Maternal 
transmissions of large alleles were more unstable with a bias toward expansions (7/15 
expansions, 3/15 contractions) and paternal transmissions were biased toward contractions 
(4/11 expansions, 5/11 contractions) disagreeing with the earlier study. However the 
Nakomoto study looked at very few transmissions. Northern and RT-PCR analysis suggests 
there may be expression of the Dirl fragment in tissues including heart, skeletal muscle and 
pancreas, though the CAG/CTG repeat sequence was included in the probe and hence may 
detect other expressed transcripts including repeats. Both studies noted that ERDA1 could be
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responsible for some of the expanded bands detected by the RED method and should be 
taken into consideration.
The bimodal distribution of ERDA1 alleles was confirmed in several different isolated 
populations including Nigerians, Papua New Guinea Highlanders, Chinese and CEPH 
reference families (Deka et a l, 1999). Nigerians had a greatly reduced frequency of alleles 
greater than 40 repeats (5.9%) compared to other populations (average 15%). Further 
investigation uncovered interruptions in the Nigerian small alleles of CAT and CAC repeats 
and the A polymorphism 3’ of the repeat, which presents as a C in expanded alleles, implying 
that these small alleles would possess enhanced stability and hence rarely give rise to 
expanded alleles in the population. When observing transmissions at this locus, there was no 
parental effect on the transmission of expanded alleles, however there was a difference in the 
nature of paternal mutations (45.9% mutation rate of 61 transmissions of large alleles, 93% of 
which are contractions), compared to maternal mutations (47.1% mutation rate of 34 
transmissions of large alleles, 75% of which are expansions). Verheyen et a l (1999) also 
found an expansion (>40 repeats) frequency of 19% in BPAD families, with instability of 65 
and 84 repeat alleles in transmission. This differed from Nakamoto et a l (1997) and aspects 
of the study by Deka et a l (1999) but agreed with Ikeuchi et a l (1998) in that the maternal 
transmission of the 65 repeat allele gave rise to expansions (67-71 repeats) and the paternal 
transmission of the 84 repeat allele gave rise to contractions (73-74 repeats). Expanded RED 
products in PD patients prompted a screen at the ERDA1 and CTG18.1 loci which concluded 
that 100% of expanded RED products could be attributal to these two loci (Schraen-Maschke 
et a l, 1999). The largest ERDA1 allele detected in PD families was 75 repeats, although 
normal alleles were also detected in patients and the 75 repeat allele was present in the 
unaffected daughter of an affected patient (Schraen-Maschke et a l, 1999). Hence ERDA1 
and CTG18.1 were discounted as contributing to the PD phenotype.
1.5 Triplet Repeats and Psychiatric Disorders
Affective Disorder is present as a spectrum of phenotypes including Bipolar Affective 
disorder (BPAD) affecting 1% of the population and Unipolar affective disorder (UPAD) 
affecting 6% of the population. BPAD can be subdivided into types I and II, consisting of 
mood swings from depression, such as low mood, sleep and appetite disturbance, 
psychomotor abnormalities, fatigue, diminished self-attitude and cognitive slowing, and in type 
I, mania such as elation, impulsivity, increased energy and activity and rapidity of speech and 
cognition. Psychiatric disorders such as BPAD are thought to be multigenic due to the
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variability in symptoms, even within families and the mode of inheritance remains unclear, 
although mothers are more likely to transmit the phenotype with a relative lack of male to male 
transmission (Gelemter, 1995). Family studies of affected probands conclude an increased 
risk of UP AD, major depressive disorder (MDD), cyclothymia (CY) and schizoaffective (SA) 
disorders to a first degree relative (Verheyen et a l, 1999). BPAD has been linked to 
chromosomes Iq31-q32 (Detera-Wadleighe ta l, 1999), 4pl6 (Blackwood e ta l,  1996), 7q31 
(Detera-Wadleigh e ta l, 1999), 11 (Mclnnes e ta l, 1996), 12q23-24 (Ewalde?al, 1998), 
13q32 (Detera-Wadleigh et al, 1999), 18 (Berrettini et a l, 1994, Stine et a l, 1995, Coon et 
a l, 1996, De bruyn et a l, 1996, Freimer et al, 1996, Mclnnes et a l, 1996, McMahon et a l, 
1997, Detera-Wadleigh e ta l, 1999), 21 (Straub e ta l, 1994 Detera-Wadleigh e ta l,  1996), 
22ql l-ql3 (Detera-Wadleigh et al, 1999) and X (Baron et a l, 1987). In particular, 
chromosome 18q has been the focus of detailed linkage analysis. Stine et a l (1995) 
demonstrated linkage at 18q21 in combined BPAD type I and II individuals, Mclnnes et al 
(1996) found highest linkage in two combined families with BPAD type I at 18q22-q23 and 
McMahon et a l (1997) found affected sib pairs had excessive allele sharing at 18q markers, 
D18S38 demonstrating the strongest linkage, but other studies have failed to detect linkage of 
BPAD to chromosome 18 (Maier et a l, 1995, Pauls et a l, 1995, Detera-Wadleigh et a., 1997)
Schizophrenia is characterised by gross disturbances of perception (hallucinations) and 
cognition (delusions and thought disorder) as well as the negative symptoms of amotivation 
and paucity of thought (Mclnnis and Margolis, 1998), affecting approximately 1% of the 
population. The disease has been linked to chromosomes 2q (Levinson et a l, 1998), 3p 
(Pulver et a l, 1995), 4q (Levinson et a l, 1998), 5q (Straub et al, 1997), 6p (Moises et al, 
1995, Wang et a l, 1995), 8p (Pulver et al, 1995), 9 (Moises et a l, 1995, Levinson et al,
1998), lOq (Levinson et al, 1998), l lq  (Levinson et al, 1998), 18q (Hovatta e ta l, 1999), 20 
(Moises et a l, 1995) and 22q (Coon et al, 1994, Pulver et a l, 1994), in genomewide scans of 
affected families. The onset of the disease and the outcome is worse in males and anticipation 
has been observed in several different studies (Asherson et a l, 1994, Chotai et a l, 1995, 
Thibaut et a l, 1995, Bassett and Husted, 1997). As described earlier, anticipation is a 
decreasing age of onset with increasing severity of symptoms within a pedigree of a disease 
family. These findings implicate expandable triplet repeats as the genetic mutation giving rise 
to schizophrenia. Hence, the RED (Repeat Expansion Detection) method (Schalling et a l, 
1993) (Figure 1.2) has been utilised to look for evidence of triplet repeat expansion 
(CAG/CTG in most cases due to the higher frequency of these expanded alleles contributing 
to disease phenotypes) in various psychiatric disorders such as BPAD and schizophrenia, 
with conflicting data.
Either a higher percentage or larger expanded RED products have been found in BPAD 
(Lindblad e ta l, 1995, Mendlewicz eta l, 1997, Verheyen e ta l, 1999) and schizophrenia 
(Morris et a l, 1995, Burgess et al, 1998, Vincent et al, 1998). In cases of BPAD, ethnicity 
(Lindblad et a l, 1995), sex of transmitting parent (Mendlewicz et al, 1997), type I or II 
symptoms (Lindblad e ta l,  1995) and age of onset (Mendlewicz e ta l, 1997, Verheyen e ta l, 
1999) have been linked with RED product size. Belgian type I affecteds have significantly 
larger RED products than Swedish or type II patients (Lindblad et a l, 1995). Increasing 
severity of symptoms (Mendlewicz et al, 1997, Verheyen et al, 1999) and a link between 
maternal but not paternal transmission and expansion of RED product (Mendlewicz et a l, 
1997) has been observed. Other studies could not replicate the positive RED findings in 
BPAD patients (Vincent et al, 1996, Li et a l, 1998, Verheyen et al, 1999, Vincent et a l,
1999). Larger RED products have also been found in schizophrenia patients (Morris et a l, 
1995, Burgess et a l, 1998, Vincent et al, 1998) with sex effects in females (Morris et a l,
1995) or males (Burgess et a l, 1998). Twins fully or partially discordant for the disease also 
demonstrated larger RED products than those discordant (Vincent et al, 1998), but no 
difference in RED product size between affected and unaffected has been found in other 
studies (Vincent et al, 1996, Laurent et a l, 1998, Li et a l, 1998).
Following on from this, groups have screened many repeat loci in order to find an expandable 
locus for BPAD and schizophrenia. One strong candidate for schizophrenia seemed to be the 
hSKCa3 gene. hSKCa3 contains 2 CAG repeats, one of which is highly polymorphic 
(Chandy et a l, 1998). Initial reports located hSKCa3 to chromosome 22ql 1, near a region 
linked to schizophrenia. Allele typing found that alleles >19 repeats were more commonly 
found in the schizophrenia group compared to controls (Chandy et a l, 1998), strengthened 
with results from Bowen et a l (1998) and Dror et a l (1999). Then hSKCa3 was shown to 
map to lq21 and not 22ql 1 (Austin et a l, 1999, Dror et al, 1999) and the point was made 
that the alleles at the hSKCa3 locus were not large enough to account for RED expansions 
observed in patients. Further work demonstrated that there was either excessive transmission 
of the smaller alleles within affected families or lack of transmission of the larger alleles (Li et 
a l, 1998, Stober et a l, 1998, Austin et a l, 1999, Wittekindt et al, 1999) or no significant 
difference between allele sizes in BPAD, shizophrenia or control individuals (Hawi et a l,
1999). A Ball restriction polymorphism (changing Serine to Glycine) in exon 1 of the 
dopamine D3 receptor gene in conjunction with a telomeric dinucleotide repeat marker 
(D3S1310) has also been investigated in schizophrenia patients (Jonsson et a l, 1999). Many 
previous reports had associations between DRD3 genotypes with various subtypes including 
males, individuals who respond to medication, individuals who have a family history of the 
disease, suffer alcohol or substance abuse or have been diagnosed with disorganised or 
undifferentiated shizophrenia. The subsequent study found no difference between the Ball
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genotypes of schizophrenics or controls (Jonsson et a l, 1999). At D3S1310 however, 
shizophrenics had a lower frequency of the 141bp allele and a higher frequency of the 143bp 
allele compared to controls. Homozygosity for the 143bp allele was the most frequent 
genotype in both patients and controls, but at a higher frequency in schizophrenics (Jonsson 
et a l, 1999). No evidence for linkage disequilibrium between this polymorphism and marker 
D3S1310 was found but now another study has uncovered several polymorphisms in novel 
exons 5’ to the named exon 1 which are currently being tested (O'Donovan and Owen, 1999).
Distribution of the polymorphic B33 CTG repeat (9-18 repeats) on chromosome 3 showed no 
difference between periodic catatonia (subtype of schizophrenia) patients and controls (Bengel 
et a l, 1998) although an increased percentage heterozygosity was observed. Schizophrenic 
and BPAD patients were typed at a polymorphic CAG repeat (6-9 repeats) in the IL9 receptor 
gene at Xq28/Yq21, showing a slight increase in the frequency of the larger of the two most 
common alleles (8 repeats) in patients, but not enough to be significant (Hawi et a l, 1999). 
Separating the samples based on sex increased the significance of association of the 8 repeat 
allele with BPAD in males, but not in females. No association was found between any allele 
and schizophrenia (Hawi et a l, 1999). The polymorphic TTA repeat (122-143bp) in the 
phospholipase A2 group IB (PLA2G1B) gene has also been investigated in schizophrenics 
(Strauss et a l, 1999). No difference was found between the distribution of the alleles in 
Caucasian or African-American controls compared to patients, the most frequent alleles being 
122/125bp (Caucasian) and 125/134/137bp (African-American). The imperfect polymorphic 
CAG repeat in the TATA-binding protein (TBP) gene at 6q27 (Imbert et a l, 1994) was typed 
in schizophrenia or BPAD patients and controls (Rubinsztein et a l, 1996). No difference was 
found between different ethnic groups (Caucasians, South African blacks, Sub-Saharan 
Africans, Asian Indians) and schizophrenia or BPAD patients. Furthermore, over 50 
CAG/CTG loci distributed on autosomal (44) and X (7) chromosomes have been screened by 
allele typing with fluorescence and radioisotope methods after the indication that there could 
be a sex effect in BPAD (ODonovan et a l, 1995). All loci were excluded for association with 
BPAD based purely on size as the largest allele detected was only 37 repeats (Guy et a l, 
1997).
During the course of investigations into the possibility of triplet repeat expansion causing 
BPAD or schizophrenia using the RED technique, both the CTG 18.1 and ERDA1 loci were 
published. This presented novel expandable trinucleotide repeat loci as possible candidates 
for BPAD and /or schizophrenia. Psychiatric patients were screened using the RED method 
with a CTG probe and though large RED products were evident, PCR allele typing at 
CTG 18.1 and ERDA1 pointed to 94% of trinucleotide repeat expansions detected by RED 
being due to expansions at these loci (Sidransky et al., 1998). Again, screening large RED
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products in BPAD individuals found that 75% were due to ERDA1 compared to 83% in 
controls (Lindblad et a l, 1998). In total, 8 out of 9 individuals with large RED products had 
either CTG18.1 or ERDA1 expansions. At the CTG18.1 locus, 19% of affected individuals 
had an expansion, compared to only 8% of controls with a significant difference between 
affected and unaffected in RED products, producing a negative correlation between CTG18.1 
repeat length and age of onset in families. Therefore, it is important to note that if both 
CTG18.1 and ERDA1 can be excluded as the cause of a large RED product, the remaining 
large products are likely to indicate the disease allele. In a study on cases of schizophrenia 
which have demonstrated expanded RED products, CTG18.1 was screened but not all RED 
products could be attributed to this locus (Burgess et al., 1998) and ERDA1 has yet to be 
investigated. Twins either cordant or discordant for schizophrenia were also analysed at 
CTG18.1 but showed no differences in repeat size, demonstrating that this locus alone is not 
responsible for the variation in RED product sizes between siblings (Vincent et a l, 1998).
Verheyen et a l (1999) reanalysed Belgian BPAD blood samples published by Lindblad et a l 
(1995) which had demonstrated that Belgian type I affecteds had significantly larger 
CAG/CTG products than controls. Both BPAD patient and control samples that had 
expanded RED products were typed at both CTG18.1 and ERDA1, with 91.3% and 81.5% 
respectively having alleles >40 repeats at either of these loci. For ERDA1, the overall allele 
distributions were significantly different between BPAD affecteds and controls. Although the 
distribution of the largest ERDA1 alleles in individuals was not different, the proportion of 
BPAD individuals with one or two expanded alleles was significantly larger in the BPAD 
affecteds and the number of large (>40 repeats) alleles was higher in BPAD affecteds than 
controls. For CTG 18.1, there was no significant difference between the allele sizes in BPAD 
individuals or controls. CTG 18.1 and ERDA1 loci were typed in BPAD families, in both 
affected and unaffected individuals (Verheyen et al., 1999). 90.2% of expanded RED 
products were accounted for by expansions at CTG 18.1 or ERDA1. CTG 18.1 was 
discounted as a BPAD gene in a particular family which had previously shown linkage to 
18q21.33-q23 (De bruyn et al., 1996) as they did not demonstrate expansions at this locus 
(Verheyen et al., 1999). However, a slight negative correlation between ERDA1 allele size and 
age of onset was observed (Verheyen et al, 1999). A study of CTG18.1 and ERDA1 allele 
sizes in Caucasian BPAD type I patients and controls however, showed no significant 
difference between the two groups, either in distributions of maximum allele sizes, the 
frequency of large alleles (>40 repeats) or between age of onset and frequency of large alleles 
(Guy et al., 1999). Subsequent comparison of RED product size and alleles at the CTG18.1 
and ERDA1 loci revealed only approximately 41% can be attributed to these loci, a much 
lower estimation than previous studies (Lindblad et al., 1998, Sidransky et al., 1998, Verheyen 
et al., 1999). Analysis of individuals with familial depression revealed an expanded ERDA1
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allele present in three generations of one family (Vincent et al., 1999). Combined symptoms 
of the maternal grandparents included schizophrenia, drug abuse and major depression. The 
proband had inherited an expansion from 102 to 115 repeats at the ERDA1 locus and also 
suffered major depression, anxiety, abuse and dysthymic disorder. Her children inherited 82 
and 115 repeats respectively but there was no data available on their health (Vincent et al.,
1999).
Given the growing number of diseases associated with trinucleotide repeats and the reports of 
anticipation in psychiatric disorders it seems likely that dynamic mutations could be a 
contributory factor. Although BPAD and schizophrenia are thought to be multigenic 
disorders, screening of novel trinucleotide repeat loci has been undertaken to try to find a 
causative mutation. The RED method gives an indication of the presence of an expandable 
trinucleotide repeat in the genome, but not its location. The RED method does seem to point 
to an increased frequency of expanded repeats in psychiatric patients and CTG18.1 and 
ERDA1 are ideal candidates. However, although there are also reports of increased expanded 
alleles at these loci in affected individuals, there is no absolute correlation between expansions 
and disease, unlike DM-1 and HD.
1.6 The SEF2-1 gene and its protein function
Discovery of the CTG18.1 locus characterised an expandable CTG repeat putatively located in 
the third intron of the human SEF2-1 gene at chromosome 18q21.1 (Breschel et al., 1997). 
SEF2-1 is one of a family of nuclear proteins designated SL3-3 enhancer factors 2 belonging 
to the basic helix-loop-helix (B-HLH) class of DNA-binding proteins. These proteins 
interact with an Ephrussi box (E box)-like motif (-NNCANNTGNN-) which gives them the 
name E proteins. E proteins can be divided into 3 types, ubiquitously expressed, tissue- 
specific and inhibitors of DNA-binding. Class IE  proteins are ubiquitously expressed and 
bind as homodimers or heterodimers with a Class II protein to an E2 box 
(-G/ACAGNTGT/G-) which have been identified in muscle and pancreas-specific enhancers. 
All Class I proteins are structurally related and well conserved in the HLH domain and include 
the proteins E12 and E47 derived from the E2A gene, HEB, SEF2-1 and daughterless of 
Drosophila which is involved in the control of sex determination and neurogenesis. Class II 
E proteins are tissue-specific and do not bind as homodimers to an E2 box. Members of 
Class IIE  proteins include MyoD, myogenin, myf-5, herculin, proteins that induce 
myogenesis and Drosophila gene products involved in neurogenesis including members of 
the achaetescute gene family (Bain et al., 1993). Id proteins are inhibitors of DNA binding
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and bind to either Class I or IIE  proteins as heterodimers. Id proteins lack the basic DNA 
binding domain and are known to bind with the least affinity to any of the E proteins.
SEF2-1 is also known as ITF-2 (Immunoglobulin Transcription Factor 2), (Henthorn et al,
1990) in human, E2-2 in mouse (Comeliussen et al., 1991) and TFE in dog (Javaux et a l,
1991). ITF-2 was discovered in 1990 (Henthorn et al, 1990) while investigating the 
Immunoglobulin heavy and K light chain gene enhancers and how they are activated by 
ubiquitous and developmentally regulated proteins. Two cDNAs were isolated which encoded 
the proteins named ITF-1 (E2A) and ITF-2 which were expressed in a variety of cell types 
and bound to the jiE5/kE2 motif found in both enhancers. ITF-1 and ITF-2 are structurally 
and functionally similar, but derive from separate genes. ITF-1 and ITF-2 interact with one 
another as proteins through their helix-loop-helix motifs and each possess a domain in the 
amino terminus that dictates transcription activation.
The SEF2-1 gene encodes four main alternative transcripts, SEF2-1A-D (although 10 
different cDNAs may have been identified (Hermann et a l, 1998)), identical except in their 5’ 
ends. SEF2-1A and B are the most prevalent transcripts, SEF2-1B being full length, SEF2- 
1A and SEF2-1D being shorter and containing an additional amino acid motif known as the 
RSRS domain 5’ to the bHLH domain (Comeliussen et a l, 1991). MITF-2A and B are the 
mouse homologues of SEF2-1A and B, but MITF-2B contains the RSRS domain (Skerjanc 
et a l, 1996). MITF-2B seems to downregulate MyoD induced expression of the cardiac a- 
actin protmoter whereas MITF-2A has no effect, but removal of the RSRS domain suggests 
this motif is not responsible for the inhibition activity (Skerjanc et a l, 1996) and in fact the 
alternative 5’ ends are responsible. It is not yet clear what role the RSRS domain may play in 
DNA-binding or protein-protein interactions, especially as the closest relatives of MITF-2, 
HEB and E2A do not contain a RSRS domain. MITF-2B transcripts have been detected in all 
cell types including stem cells, cardiac muscle, skeletal muscle, neuroectoderm, mouse brain, 
mouse liver, mouse leg muscle and heart, all in equal amounts. MITF-2 A is present in all 
samples that contain neurons such as neuroectoderm, skeletal muscle and brain, but at variable 
levels in other tissues.
SEF2-1 has also been implicated in the expression of Somatostatin Receptor 2 (SSTR2), one 
of a family of 7-helix transmembrane spanning receptors which regulate potassium and 
calcium channels and cytoplasmic signal transduction pathways (Rens-Domiano and Reisine,
1992). Somatostatin receptors are highly expressed in the hypothalamic-hypophyseal system, 
regulating the adenohypophyseal release of growth hormone (GH), thyroid stimulating 
hormone (TSH) and prolactin (Brazeau et al, 1972), the somatostatinergic system in the
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central nervous system, modulating cognitive and vegetative functions (Epelbaum et a l , 1994) 
and the gastroenteropancreatic system of endocrine cells regulating gastric acid and 
gastroenteropancreatic hormone release (Nelson-Piercy et a l, 1994). SSTR2 and SSTR4 are 
also expressed in the murine embryo brain (Maubert et a l, 1994). By screening a murine 
brain expression library with a probe made up of repeated units of the SSTR2 promoter, 
MITF-2B was found to bind to an E box within 90bp of the ATG start site (Pscherer et a l, 
1996). Direct comparison of the submitted cDNA sequences from Skerjanc and Pscherer has 
revealed some discrepencies in MITF-2B. The definitions of the different isoforms of ITF- 
2/SEF2-1/E2-2 includes whether the RSRS domain is present, identical 3’ ends and differing 
5’ ends. However, MITF-2B as sequenced by Pscherer does not contain the RSRS domain 
and has differing 5’ and 3’ ends. MITF-2B defined by Skerjanc seems to be the correct 
mouse homologue of SEF2-1B as published by Comeliussen. Further expression work on 
SEF2-1 was carried out with a human SEF2-1 probe, detecting a 7.5 Kb transcript in brain, 
heart, placenta, skeletal muscle and lung of the human adult, heart, lung and highly in brain of 
the human embryo, heart, brain, lung and skeletal muscle in mouse and in whole murine 
embryo (Pscherer et a l, 1996). Gel retardation assays demonstrated that SEF2-1 GST fusion 
protein alone binds to the E box, but requires at least a second protein endogenous to the cell 
type to activate transcription of SSTR2. TFIIB did form a second complex with SEF2-1 
when it was bound to DNA, raising the possibility that SEF2-1 can initiate transcription by 
recruiting transcription factors to the promoter of SSTR2 (Pscherer et a l, 1996). Further 
characterisation of proteins binding to the SSTR2 promoter uncovered MIBP1, a sequence- 
specific DNA-binding zinc finger which binds to a TC-rich sequence directly upstream of the 
E box and enhances expression (Dorflinger et al, 1999). MIBP1 was found to directly 
interact with the SEF2-1 protein and the specific bHLH domain was responsible. MIBP1 did 
not interact with either E 12 or E47 (alternatively spliced products of the E2A gene), 
suggesting a possible role for the RSRS domain in protein interactions. Furthermore, MIBP1 
demonstrated an identical expression pattern with SEF2-1 and SSTR2 in murine heart, 
skeletal muscle and brain, specifically the cerebra cortex, hippocampus and corpora amygdala 
(Dorflinger et a l, 1999).
SEF2-1 protein has been hypothesised to work in conjunction with HEB and E2A proteins in 
the development of B-cells (Zhuang et al, 1996). Mice homozygous for SEF2-1 or HEB 
mutations can produce B-cells, but have reduced numbers (50%) of pro-B cells indicating 
both genes are not essential for the establishment of B-lymphocytes. Homozygous lack of 
SEF2-1 and heterozygous lack of E2A results in embryonic lethality. It was suggested that 
SEF2-1 and HEB may form heterodimers with Id E proteins which inhibit DNA binding. By 
preventing the Id proteins binding to a third E protein, E2A, it is left to form homodimers and
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bind to an enhancer or E box in the promoter region of a gene(s) controlling B lymphocyte 
development (Zhuang etal., 1996).
As SEF2-1 is ubiquitously expressed it is likely that it plays many roles in the differentiation 
and development of various tissues. Increased expression of SEF2-1 has been discovered in 
prostate cancer cells of three different patients compared to normal tissue (Liu et a l, 1997). 
SEF2-1 lacking RSRS binds to a sequence in the brain-specific FGF-l.B promoter and 
represses expression (Liu et a l, 1998) whereas expression is not affected if the RSRS is 
present. An interesting observation was that the human brain contains proportionally more 
SEF2-1 with the RSRS domain than without (Liu et a l, 1998) which is likely to be due to 
observed elevated expression of SEF2-1D (Skerjanc et a l, 1996). Calcium loaded calmodulin 
has also been implicated in regulating SEF2-1 binding to DNA (Hermann et a l, 1998), and 
interaction is determined by sequence directly 5’ to the bHLH domain. Could this be a 
function of the RSRS domain?
1.7 Genomic instability in Cancer
1.7.1 Hereditary Non-polyposis Colon Cancer (HNPCC)
HNPCC can affect as many as 1 in 200 individuals and accounts for 3-6% of all colon 
cancers. An HNPCC kindred is defined by the Amsterdam criteria as those in which three or 
more closely related family members in at least two successive generations have had 
histologically verified diagnosis of colorectal cancer, at least one of whom was diagnosed 
before 50 years of age (Vasen et a l, 1991). The Amsterdam criteria has now been revised to 
incorporate HNPCC-associated cancers of the endometrium, small bowel, ureter or renal 
pelvis in addition to the colon (Vasen et al, 1999). HNPCC had been linked to chromosome 
2pl6-15 (Peltomaki et al, 1993) and 3p21 (Lindblom et a l, 1993) and is often divided into 
two subgroups, type I and type II. Type I have a hereditary predisposition to colorectal cancer 
that is distinguished from sporadic colorectal cancer by a younger age of onset and the 
carcinomas are often observed in the proximal colon. Type II patients have an increased risk 
for cancers of the uterus, ovary, breast, stomach, kidney, small intestine, skin and larynx in 
addition to the colon. Significant changes in (CA) dinucleotide allele lengths were observed 
more frequently in HNPCC than sporadic tumours at six different loci, suggesting the 
underlying cause of HNPCC could be a defect in mismatch repair (Aaltonen et a l, 1993).
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The majority of HNPCC cases are now known to be caused by inherited germline mutations 
in one of five DNA mismatch repair enzymes hMLHl (Bronner et a l, 1994, Papadopoulos et 
a l, 1994, Wheeler et a l, 1999), KMSH2 (Leach et a l, 1993), hPMSl (Nicolaides et a l, 1994), 
hPMS2 (Nicolaides et a l, 1994) or hMSH6 (Akiyama et a l, 1997, Miyaki et a l, 1997). The 
role of the DNA mismatch repair (MMR) pathway in conjunction with the nucleotide excision 
repair (NER) pathway is to detect mismatches that occur during replication and correct them 
by excising the incorrect strand and replacing it with a new, correctly synthesised strand. 
Extensive research has been carried out to characterise the MMR proteins in E.coli and yeast 
to precisely define their function, however even though the respective homologues have been 
found in humans, their precise roles are elusive. For example, in E.coli the mismatch repair 
pathway is well defined and involves the co-operation of several proteins known as the 
“Repairosome” (Figure 1.3). Within the repairosome, it is known that MutS recognises and 
binds to the mismatch in the DNA (Su and Modrich, 1986), with MutH binding to 
hemimethylated GATC sites on the incorrect strand (Welsh et a l, 1987). MutL is then 
recruited by MutS, inactivating MutH (Grilley et a l, 1989). MutU (UvrD helicase) acts in 
conjunction with exonucleases (Reel and Exol) to excise the unmethylated strand and the new 
strand is now synthesised in place of the old, incorrect strand by DNA polymerase III, single­
strand DNA-binding protein and DNA ligase (Matson and George, 1987, Lahue et a l, 1989, 
Modrich, 1989, Modrich, 1991, Cooper et al, 1993). In yeast, there are seven homologues of 
MutS (MSH1-6 and HSM3) and four MutL homologues (MLH1-3 and PMS1) (Kirkpatrick,
1999). MSH1-3 and 6 are involved in mismatch repair and MSH4 and 5 are involved in 
chromosomal crossover and segregation (Kirkpatrick, 1999). No MutH homologues have 
been defined but yeast does not methylate its DNA and hence this protein would not have a 
function.
The human homologue of MSH2 (HMSH2) is made up of 16 exons, cloned using degenerate 
primers to conserved sequences of the known MutS homologues and localised to 
chromosome 2 (Fishel et a l, 1993). As some HNPCC families had been linked to 
chromosome 2p 16-15 (Peltomaki et al, 1993) hMSH2 was investigated as a potential 
candidate gene. Only 48% of the MSH2 sequence was examined for mutations, but 29% of 
the 27% of tumours that demonstrated dinucleotide repeat instability had a transition of T to C 
in this gene. Analysis of only exon 13 of HMSH2 revealed two mutations of T to C transition 
and a G deletion in four separate families (Jeon et al, 1996). Liu et a l (1996) noted large 
hMSH2 genomic deletions in other patients encompassing exons 4-8 and 1-6. HNPCC 
families that did not have nucleotide changes in HMSH2 were investigated further and four 
different deletions covering parts of exons 1, 2, 3 and 6 were uncovered, but only in Dutch and 
not Norwegian kindreds (Wijnen et al, 1998). In total, 24% of HNPCC families defined by
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the Amsterdam criteria have a hMSH2 mutation, 27% of which are deletions and 73% are 
point mutations (Wijnen et a l, 1998).
hMLHl, hPMSl and hPMS2 were discovered by scanning a database for sequences with the 
highest similarity to yeast and bacterial mutator genes, designing PCR primers and localising 
the genes to chromosomes 3, 2 and 7 respectively (Papadopoulos et a l, 1994). hMLHl was 
further localised to 3p21.3 and shown to be expressed in colon, lymphocytes, breast, lung, 
spleen, testes, prostate, thyroid, gall bladder and heart (Papadopoulos et a l, 1994). Due to the 
previous linkage of HNPCC families to 3p21 (Lindblom et a l, 1993), hMLHl cDNA from 
normal and HNPCC individuals was sequenced and a deletion of a full exon was found in 
affected Finnish individuals with a common ancestor. Other pathogenic mutations included 
4bp deletions and insertions giving rise to frameshifts, altering the carboxy terminus which is 
identical in yeast and humans, suggesting it has a very important role. In all, 90% of families 
linked to 3p had hMLHl mutations (Nicolaides et a l, 1994). Bronner et a l (1994) also 
isolated hMLHl by using degenerate primers to conserved sequences in bacteria and yeast 
MutL genes. They noted that the last 13 amino acids are identical between yeast and human 
MLH1. hMLHl was mapped to 3p21.3-23, and a C to T transition detected in an affected 
family, hypothesised to interfere with the conformation of the protein. Han et a l (1995) 
published that the hMLHl gene sequence is made up of 19 exons over lOOkb and detected 
misense, frameshift and splice altering mutations in type II patients who also developed 
cancers of the pancreas, endometrium, ovary or skin. Liu et al (1996) detected a C to T 
transition in hMLHl in one patient heterozygous in normal tissue and homozygous in 
cancerous colon. Other mutations included deletion of exon 15 and G to A transitions in 
intron 14 and exon 15. Again, the alleles were heterozygous in normal tissue but 
homozygous in cancerous tissue. This implies that the mechanism of tumour development 
involves inheritance of a mutated allele and loss of function of the second allele occurring 
through somatic mutation. Ten hMLHl and 4 hMSH2 mutations were detected in 15 families 
from another study, ranging from transitions to deletions of whole exons (Liu et a l, 1996). 
Patients screened for hMLHl and hMSH2 mutations demonstrate that 38% of hMLHl 
mutations are in exons 15 and 16 (Wijnen et a l, 1997). 49% of families fulfilling the 
Amsterdam criteria have mutations in hMLHl or hMSH2 compared to only 8% of families 
where one or more of the criteria were not fulfilled.
Inter-ethnic differences can alter the frequency of hMLHl and hMSH2 mutations in HNPCC 
families. 24% of HNPCC in Japanese is due to hMLHl mutations (Han et a l, 1995), 31% 
and 33% of cases in North America are due to hMSH2 and hMLHl respectively (Liu et al,
1996), whereas in Finland 83% of affected families are due to hMLHl and only 3% due to 
hMSH2, probably attributed to a founder effect (Nystrom-Lahti et a l, 1996). Chan et al,
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(1999) detected an amino acid change in exon 9 of hMSH6 and nucleotide changes and 
insertions mainly resulting in stop codons have been detected in exons 2,4, 8 and intron 10 
(Wu et a l, 1999). Haplotype analysis of flanking single nucleotide polymorphisms in 
patients with a hMSH6 T insertion in exon 4 also suggests a founder effect (Wu et a l, 1999). 
hPMSl and hPMS2 have been subsequently localised to 2q31-33 and 7p22 respectively 
(Nicolaides et a l, 1994) and in 40 HNPCC individuals screened for MMR mutations, 45% 
were in hMLHl or hMSH2 and in the remaining 55%, a C to T transition was discovered in 
hPMSl and a deletion in hPMS2 (Nicolaides et a l, 1994) but not all mutations were 
accounted for. Nucleotide substitutions and deletions in MMR genes do not account for all 
HNPCC cases and in individuals with as of yet unidentified sequence alterations, 
hypermethylation of the hMLHl promoter has been discovered in tumour samples, resulting 
in no expression of the protein (Wheeler et a l, 1999). To date, hypermethylation of hMSH2, 
hPMSl, hPMS2 or hMSH6 has not been detected.
Once heterozygosity of a MMR gene is lost, loss of post-replicative DNA mismatch repair 
increases mutation rates 100-600 times above normal levels (Bhattacharyya et a l, 1994, 
Eshleman et a l, 1995). This mutator phenotype is described as replication error positive 
(RER+) with the appearance of microsatellite instability (MIN) and a rapid accumulation of 
mutations in genes important for cell growth which leads to tumour development. RER- 
cancers tend to be aneuploid, demonstrating large alterations of the genome and mutations in 
APC, KRAS and p53 are common. RER+ tumours are diploid, do not show major 
chromosomal rearrangements and very few mutations in APC, KRAS or p53. These two 
different types of genomic instability suggest there are two distinct pathways of progression 
from premalignant to carcinoma cells (Eshleman and Markowitz, 1996).
It has been postulated that 75-100% of HNPCC tumours demonstrate microsatellite instability 
whereby the size of alleles differs between normal and cancerous tissue from the same 
individual (Aaltonen et al, 1993, Lindblom et al, 1993, Aaltonen et al, 1994), In fact, direct 
comparison of sporadic and HNPCC tumours found 83% of sporadic were MIN- (stable) 
and 85% of HNPCC were MIN+ (Pedroni et a l, 1999). Ionov et a l (1993) and Thibodeau 
et a l (1993) demonstrated that HNPCC tumours and some sporadic colorectal cancers exhibit 
widespread microsatellite instability on different chromosomes. Dinucleotide repeats (usually 
CA) are the most frequent type of repeat to be analysed due to their availability in the genome 
(estimated to be about 50,000-100,000) and their relative stability, particularly in transmission.
Two different dinucleotide (CA) and mononucleotide (A) repeats were analysed in HNPCC 
individuals with 92% displaying microsatellite instability and 81% of those were unstable at 
all four loci studied (Liu et a l, 1996). Wijnen et a l (1997) analysed seven dinucleotide, two
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trinucleotide (including the DRPLA locus) and two tetranucleotide repeats in blood and 
tumour DNA from 24 patients. 27% of AMS- (families not fulfilling Amsterdam criteria) and 
67% of AMS+ (families fulfilling Amsterdam criteria) showed microsatellite instability, but of 
the AMS-, MMR mutations could not be detected. Patient groups split into HNPCC, 
symptoms similar to HNPCC and sporadic demonstrated that sporadic cancers have 
decreased levels of microsatellite instability at less loci and patients with hMLHl mutations 
had a higher rate of MIN than patients with hMSH2 mutations (Lamberti et a l, 1999). 
Observations from patients with hMSH6 mutations showing low or no microsatellite 
instability led Wu et a l (1999) to evaluate 15 markers in tumours of this type. As well as 
BAT-26 (a mononucleotide marker commonly unstable in HNPCC tumours), D2S123 (the 
closest dinucleotide marker to hMSH2) and D18S58, they also included a trinucleotide repeat 
(FABP2), a tetranucleotide repeat (D15S1232) and BAT-17 which comprises a 
mononucleotide (A) marker in exon 10 of hMSH6. As expected, overall instability was low in 
both colon and endometrial cancers studied, only one endometrial tumour being classed as 
MSI-high (unstable at > 33% of loci). In addition to the hMSH6 mutation in this individual, 
an hMLHl frameshift mutation was also discovered that would probably contribute to the 
increase in MSI. None of the tumours demonstrated instability at either the tri or 
tetranucleotide loci, the two most frequent markers showing instability being D2S123 and 
D18S58 (43% of tumours) (Wu et a l, 1999). Data from the mononucleotide markers 
however did not confirm either way whether hMSH6 mutations would have a specific effect on 
polymorphic A tracks as had been suggested due to its involvement in repairing single 
nucleotide mismatches (Drummond et al, 1995). Given the Amsterdam criteria which 
stipulates HNPCC individuals develop symptoms prior to 50 years of age, Chan et a l (1999) 
compared individuals who had developed colon cancer at either less than 46 years or greater 
than 46 years of age and found a significant effect of age with microsatellite instability. Ten 
different loci including D2S123, D3S1067 (the closest dinucleotide marker to hMLHl), 
D18S58 and BAT-26 were analysed and those tumours demonstrating instability at 4 or more 
loci were designated MSI (microsatellite instability)-high while tumours showing instability at 
less than 4 loci were designated MSI-low. Of the younger than 46 years of onset age group, 
83% were MSI-high compared to 53% of the older than 46 years of onset group (Chan et a l, 
1999). Altering the age boundary to 36 years further increased the incidence of MSI-high in 
the younger set compared to the older set.
Other factors that have an effect on microsatellite instability include whether the tumours are 
metachronous (i.e. metastasised) or synchronous, their position in the colon or whether MMR 
genes are hypermethylated. Analysis of markers including BAT-26, D2S123 and D18S57 
found an increased number of sporadic tumours demonstrated MEN+ if metachronous rather 
than synchronous (from 14% to 19%), whereas HNPCC tumours displayed the opposite
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trend (from 89% to 75%) (Pedroni et a l, 1999). This suggests that two different mechanisms 
of tumour formation are operating in sporadic and HNPCC tumours. Tumours that were in 
the right side of the colon were also more frequently MIN+ than those positioned in the left 
or rectal sides (Pedroni et a l, 1999), though it is not clear why tumour position would have an 
effect. Previous studies had already found increased microsatellite instability in hMLHl 
defective tumours compared to tumours defective in other MMR genes (Lamberti et a l, 1999, 
Wu et a l, 1999) and with the discovery that methylation of the hMLHl promoter can also 
inactivate the gene, Kuismanen et al (1999) investigated colorectal tumours for an association 
between MIN+ and methylation status of hMLHl. 73% of sporadic colorectal tumours 
showed alterations in DNA methylation compared to normal colon tissue, and 61% of MIN+ 
tumours showed the presence of methylation at sites that were not methylated in normal tissue 
DNA. The opposite was true for MIN- sporadic tumour DNAs in which 53% displayed the 
absence of methylation at sites that were methylated in normal DNA (Kuismanen et a l, 1999). 
However, when comparing hMLHl mutated MIN+ HNPCC tumour DNA to the sporadic 
MIN+ cases, no bias was found in the methylation pattern at the same sites and so it seems 
that promoter hypermethylation is a special characteristic of the true sporadic MIN+ subset 
and not MIN+ cases as a whole (Kuismanen et a l, 1999). Investigations into whether other 
genes were also hypermethylated in the sporadic tumours revealed that a significant 
proportion (26%) of the MIN- that were hypomethylated at hMLHl were also 
hypomethylated at the calcitonin gene which is a well characterised methylation target in 
tumours. MIN+ tumours hypermethylated at hMLHl were also hypermethylated at calcitonin 
(Kuismanen et a l, 1999) and so it seems that there are different development pathways in 
MIN+ and MIN- tumours.
The contrasting data available for different types of tumours suggests that different 
mechanisms are contributing towards tumour formation. HNPCC tumours demonstrate more 
widespread microsatellite instability, whereas sporadic, RER- colon tumours have elevated 
mutations in KRAS and p53. Inherited germline mutations in DNA mismatch repair genes 
explained the differences between the two types, with new mutations being documented 
regularly. The latest DNA repair gene to be identified, MLH3 (Lipkin et a l, 2000) may shed 
more light onto the interactions between these proteins and why mutations in hMLHl and 
hMSHl have more severe consequences than mutations in hPMSl, hPMS2 or hMSH6.
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1.7.2 Ovarian Cancer
Ovarian cancer accounts for 4% of all cancers in women and 5-10% of these are hereditary. 
Ovarian cancer can be divided into various subtypes classed as low malignant potential (LMP) 
or non-invasive, endometrioid, mucinous (endocervical), serous (tubal) and undifferentiated 
with declining survival rates respectively, and then further subclassified into benign, borderline 
and malignant according to their degree of proliferation, cytological atypia (i.e. different to the 
surrounding tissue) and the presence or absence of stromal invasion (Diebold, 1999). LMP, 
endometrial and mucinous ovarian cancer are usually detected earlier (usually at FIGO - 
International Federation of Gynecology and Obstetrics- stage I) than serous or 
undifferentiated (usually at FIGO stage II or III) which probably contributes to the declining 
survival rates. LMP (borderline) serous tumours develop 10-15 years earlier than invasive 
serous and do not involve stromal invasion, resulting in a good prognosis.
The inheritance patterns of ovarian cancer can be divided into three subtypes : (a) site-specific 
in which only ovarian cancers occur (10-15% of inherited ovarian cancer cases), (b) breast- 
ovarian cancer syndrome in which families show excess breast and ovarian cancer 
development (65-75% of cases) and (c) ovarian cancer associated with HNPCC type II (10- 
15% of cases) (Bewtra et a l, 1992, Boyd and Rubin, 1997). Various oncogenes and tumour 
suppressors important to the development of ovarian cancer have been studied, including p53 
(17pl3.1), BRCA-1 (17q21), BRCA-2 (13ql2.3), ERBB2 (17q21.1), MYC (8q24), KRAS 
( 12pl2.1), BCL2 (18q21.3) and the cyclin D1 gene(llq l3). The BRCA-1 gene consists of 
22 exons distributed over 100 kbp and putatively codes for a transcription factor that is 
expressed in rapidly proliferating tissues undergoing differentiation (Miki et al., 1994). The 
BRCA-2 gene consists of 26 exons distributed over 70 kbp and possesses sequence and 
expression pattern similarity to BRCA-1 (Tavtigian et al., 1996). Mutations in BRCA-1 and 
BRCA-2 are responsible for approximately two thirds of the breast-ovarian cancer syndrome 
and the range of mutations is so numerous that most are found in only one or two families 
(Offit, 1996). Germline mutations in BRCA-1 are responsible for approximately 80% of 
hereditary ovarian cancers occurring in breast and ovarian cancer syndrome with 89% of these 
ovarian tumours being serous or undifferentiated (Boyd and Rubin, 1997), whereas the 
incidence of ovarian cancer in BRCA-2 families is very low with only late onset development 
(Takahashi et al, 1996). It is also important to note that ovarian cancer is most likely to occur 
if the inherited mutation is in the first two-thirds of the BRCA-1 gene and that various non- 
pathogenic polymorphisms of the BRCA-1 gene have been found to be associated with ovarian 
cancer in families (Janezic et a l, 1999) agreeing with an earlier study demonstrating that an 
increased number of patients had the L871P polymorphism compared to controls (Durocher 
et a l, 1996). The frequency of BRCA-1 and BRCA-2 mutations in sporadic ovarian cancers is
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low, although deletions of 17q and 13q are frequent in tumours of this type (Jacobs et al, 
1993, Kirchweger et a l, 1994), suggesting that BRCA-1 and BRCA-2 have a role in the 
development of hereditary cancers and loss of other genes close to them may be responsible 
for the development of sporadic cancers.
KRAS mutations are more frequent in mucinous (45-75%) than nonmucinous (14-32%) 
ovarian neoplasms (Enomoto et a l, 1991, Pieretti et al, 1995). In fact this is what 
distinguishes them from other histological types and can be detected in benign, borderline and 
malignant tumours with increasing frequency (Pieretti et al, 1995, Cuatrecasas et a l, 1997). 
The detection of these KRAS mutations in all three subtypes suggests that they are an early 
event in the development of ovarian mucinous carcinomas. ERBB2 codes for a cell surface 
glycoprotein homologous to the epidermal growth factor receptor and amplification or 
overexpression is common in breast and ovarian carcinomas (Slamon et a l, 1989) and 
associated with a poor prognosis (Berchuck et a l, 1990). p53 is a tumour suppressor gene 
encoding a nuclear phoshoprotein involved in the regulation of cell division and mutations 
resulting in prolonged half-life of the protein occur in approximately 60% of tumours 
(Matias-Guiu and Prat, 1998). p53 mutations occur more frequently in ovarian carcinomas 
(Milner et a l, 1993, Frank et a l, 1994, McManus et al, 1994) than borderline tumours 
(Wertheim et a l, 1994, Kupryjanczyk et al, 1995) and since ovarian cancer is not 
characteristic of Li Fraumeni families inheriting a germline p53 mutation and accumulation of 
the protein does not occur in FIGO stage I, this suggests that p53 mutations are not early 
events in ovarian cancer.
BCL2 is an antiapoptotic protein regularly found in non-neoplastic epithelium of the ovary 
(Henriksen et a l, 1995) and hence expression is associated with a good prognosis. In fact 
BCL2 expression seems to help counteract the p53 adverse effects when coexpressed at the 
same time, resulting in a better prognosis (Diebold et a l, 1996). The cyclin D1 gene is a 
member of mammalian cyclins divided into five major subclasses (A-E). Cyclins C, Dl-3 and 
E regulate the G1 check point of the cell cycle whereas cyclins A and B 1-2 regulate the 
transition to mitosis (Matias-Guiu and Prat, 1998). Increased expression of cyclin D1 has 
been found in 26% of ovarian tumours, most commonly associated with borderline and well- 
differentiated carcinomas (Worsley et a l, 1997).
Each class of ovarian cancer has various levels of genome instability and hence different levels 
of microsatellite instability. Many studies have focused on invasive ovarian tumours with few 
benign or LMP cases included solely due to late detection in patients, but it is clear that as the 
tumours progress to more aggressive stages, MIN+ is less evident and LOH and mutations in 
oncogenes and tumour suppressors are more frequent (Fujita et a l, 1995, King et a l, 1995,
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Pieretti et a l, 1995, Phillips et al., 1996, Tangir et al, 1996, Shih et al, 1998, Wiper et al, 
1998). In order to class a tumour as MIN+, two out of at least five microsatellite markers 
have to demonstrate instability when compared to normal tissue (either blood or non- 
tumourous) but in many studies only one unstable locus classes the tumour as MIN+. When 
analysing microsatellite instability, either a small number of microsatellite markers are 
analysed in large numbers of tumours with varying subtypes, or a broad spectrum of markers 
are analysed in only one or two subtypes of carcinoma. Shih et a l (1998) analysed 69 
microsatellite markers distributed over all autosomes including D2S123, D17S5, D17S855, 
D17S1322, D18S50 and the X chromosome in 31 LMP tumours and 23 cystadenomas and 
found no microsatellite instability or loss of heterozygosity (LOH - i.e. one allele is lost).
Due to reports of frequent LOH at chromosome 17pl3 (location of p53 and other candidate 
genes OVCA1, OVCA2 and HIC-1) in both early and late-stage tumours (Dodson et a l, 1993, 
Foulkes et a l, 1993, Phillips et a l, 1993), five chromosome 17pl3 markers including one 
intragenic to p53 were analysed in early-stage epithelial ovarian cancers (Wiper et a l, 1998). 
Of the 29 tumours analysed, two displayed microsatellite instability at marker D17S695, while 
the majority had increasing LOH with more advanced stages of tumour progression in this 
region. However, one of the MIN+ samples may have been from a HNPCC family as the 
patient’s mother died from colon cancer (Wiper et a l, 1998). This agreed with an earlier 
study which discovered MIN+ on chromosome 17 in only one sample out of 57 sporadic 
ovarian carcinomas classed into various subtypes and at different FIGO stages (Phillips et a l, 
1996). This tumour came from an individual whose father had died of colon cancer and who 
was herself diagnosed 20 years earlier than the average age of onset in this study. The tumour 
type was serous FIGO stage III (Phillips et a l, 1996). A second extensive study of 
chromosome 17 analysed 20 markers distributed on both arms which encompassed p53 and 
BRCA-1 in endometrioid, mucinous and serous ovarian tumours of LMP, low, medium and 
high grade types (Pieretti et al, 1995). One marker on each of the remaining autosomes and 
the X chromosome was also analysed for MIN and LOH status as well as KRAS activation in 
the tumour samples. The results demonstrated that increasing severity of ovarian cancer, 
either in subtype or grade is associated with decreasing levels of MIN+ and increasing LOH 
(Pieretti et a l, 1995). LOH on chromosome 17 is rare in mucinous tumours, whereas 
increasing loss of sections of this chromosome seem to be associated with advancing stages 
of serous carcinomas. Mucinous tumours also have significantly higher levels of KRAS 
activating mutations than other types.
Analysis of LOH at 12 markers over 8 chromosomes including 17q21 (D17S1322) and 
18q21 (D18S34) confirmed that widespread LOH is a feature of invasive carcinomas whereas 
borderline tumours have very little LOH, the most commonly affected markers being near the 
p53 and BRCA-1 loci (Saretzki et al, 1997). Generally, increased LOH is associated with
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either advanced FIGO stages or poor differentiation but not survival outcome. Microsatellite 
markers on chromosome 3 distributed throughout both arms demonstrated a significant 
difference between borderline and invasive carcinomas in regard to LOH and MIN status 
(Tangir et al., 1996). Borderline tumours (BOT) which generally have a more favourable 
prognosis possessed very little LOH (5.6% versus 39%) but greater frequency of MIN+
(28% versus 6.5%) than invasive tumours, however the few borderline tumours displaying 
MIN+ were classed as serous, whereas the mucinous borderline tumours did not demonstrate 
MIN+ status (Tangir et al., 1996). Other studies on the same BOT samples showed that 
MEN was not evident at 46 other markers on chromosomes 6q (Rodabaugh et a l, 1995), 9p 
(Rodabaugh et a l, 1995), 17p (Wertheim et a l, 1996) and 17q (Tangir etal., 1996). Again, 
analysis of FIGO stage I-IV carcinomas confirmed the low incidence of MIN in ovarian 
cancer, and of the tumours that did display MIN+, though only at one locus out of four, they 
were all classed at FIGO stages I-M (Park et a l, 1995).
Comparing ovarian tumour and blood samples from individuals with or without a family 
history of cancer found no significant difference in the MIN status in either family history or 
sporadic occurrence, age at diagnosis or histopathology at 3 dinucleotide markers 
(Arzimanoglou et a l, 1996). The rate of MIN+ was low as previously reported, only 11/90 
tumours demonstrating instability at least one marker out of three, the most frequently affected 
being D2S123 (hMSH2 marker). MIN+ could be divided into three types, either loss of an 
allele (LOH), additional bands or shifting of the progenitor alleles. Again, there was no 
correlation between MIN+ type or histopathology, although the only tumour displaying 
MIN+ at all three markers came from a suspected HNPCC family (Arzimanoglou et a l,
1996). King et a l (1995) also found low rates of MIN+ in ovarian neoplasms (17%) 
although only two markers were analysed, a di- and tetranucleotide {GABARBI) repeat on 
chromosomes 5ql 1-13 and 4p 12-13. All seven of the MIN+ tumours were unstable at the 
tetranucleotide marker and two of these were also unstable at the dinucleotide marker.
Patients over the age of 50 years at diagnosis had a slightly higher rate of MIN+ as did those 
with additional tumours, either synchronous or metachronous and all MIN+ tumours were 
classed as FIGO stage I and III (King et al, 1995). Fujita et a l (1995) also found increasing 
MIN+ at four dinucleotide markers on chromosomes 5q, 15q, 17p and 18q in the less 
aggressive endometrioid and mucinous tumours than the serous carcinomas, however MIN-i- 
status was found to be associated with more advanced FIGO stages (although a small number 
of tumours were analysed) which is contrary to the previous studies detailed above. hMSH2 
mutations were associated with three of the seven MEN+ tumours, however the extent of 
MIN+ in these samples was not different to the remaining four samples (Fujita et a l, 1995).
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Comparing LOH, MIN status and mutations in oncogenes such as KRAS suggests there are at 
least two different mechanisms of tumour progression in ovarian cancer. In fact, the most 
common genetic change in ovarian cancers seems to be loss of chromosome 17, followed by 
LOH on other chromosomes, mutations in genes such as KRAS and then mismatch repair 
mutations giving rise to MIN+ (Pieretti et a l, 1995). Although the rate of MIN+ in ovarian 
cancer is low, it occurs more frequently in the early stage tumours than the late stages. This 
MIN+ status is relatively focal and not widespread in the genome, whereas LOH is more 
frequent in late stage tumours, especially on chromosome 17 and more widespread. More 
aggressive invasive epithelial ovarian cancers have increased mutations of oncogenes such as 
KRAS and p53, but some types of tumour, such as mucinous have elevated KRAS mutations 
that may define their type.
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oligonucleotides
ANNEALING
Genomic DNA (CAG)
L IG A T IO N
D ENATURATIO N
C YC LIN G
Products = Multimers of (CTG)17 
oligonucleotides
Figure 1.2 Schematic representation of the Repeat Expansion Detection 
Method (RED). An oligo comprised of multimers o f the repeat o f interest is annealed 
to denatured genomic DNA and hybridised to the target at a tem perature near its m elting 
point. Ligase then binds adjacent oligos, producing a mixed population o f single 
stranded DNA molecules which can be separated by agarose gel electrophoresis.
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MutH
MutS
MutH
M utL
Figure 1.3. Schematic representation of the process of DNA mismatch 
repair in E.coli. W i t h i n  the repairosome, it is known that MutS recognises and binds to the 
mismatch in the DNA, with MutH binding to hem 1 methylated GATC sites on the incorrect 
strand. MutL is then recruited by MutS, inactivating MutH. MutU (UvrD helicase) acts in 
conjunction with exonucleases (R ed  and Exol) to excise the unmelhylaled strand and the new 
strand is now synthesised in place o f the old, incorrect strand by DNA polym erase III, single­
strand DNA-binding protein and DNA ligasc.
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Chapter 2
Materials and Methods
2.1 Preparation of DNA from tissues
Semen samples were donated by patients attending the Infertility Clinic Unit of the Western 
Infirmary, Glasgow and subsequently supplied by Dr. Mena Behan. Samples were 
refrigerated following donation, acquired within 24 hours and frozen at -20°C upon receipt. 
Sperm counts ranged from l->500 millions/ml.
2.1.1 Crude preparation of DNA from human tissue
In order to approximate triplet repeat allele lengths at the CTG18.1 and ERDA1 loci, lOOjil of 
semen or blood was resuspended in 900jil of 1 x SSC and the cells pelleted by centrifugation 
at 4,000 rpm for 5 minutes in a bench top centrifuge at room temperature. The supernatant 
was decanted. lOOpl of lysis buffer and 15|il of 20 mg/ml proteinase K was added to the 
pelleted cells and the mixture incubated overnight at 60°C. Following vigorous vortexing, 
cellular debris was pelleted at 4,000 rpm for 5 minutes in a bench top centrifuge at room 
temperature. A small amount of DNA from the supernatant (approx lpl) was made to 50jil 
with distilled water in a screw top Eppendorf tube resulting in a final DNA concentration of 
approximately 5ng/pl. The proteinase K was inactivated by incubating the diluted DNA at 
95°C for 5 minutes. The samples were stored at -20°C until required.
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2.1.2 Preparation of DNA from semen samples
To directly observe mutations in the male germline cells, good quality DNA needed to be 
isolated from sperm. The following protocol selectively enriches sperm DNA from the semen 
samples in preference to any somatic cell contamination that may be present. The protocol is 
adapted from the Nucleon Biosciences BACC III genomic DNA extraction kit blood and cell 
culture protocol.
Selected frozen semen samples were thawed on ice and 500|il was resuspended in 2ml of 1 x 
SSC. The cells were pelleted by centrifugation at 3,000 rpm for 2 minutes in a bench top 
centrifuge at room temperature, the supernatant discarded and the pellet resuspended once 
again in 2ml 1 x SSC. In order to remove any somatic cell contamination, 200|til of 10% SDS 
was added, the samples inverted several times and the intact sperm cells pelleted at 3,000 rpm 
for 2 minutes at room temperature. 500pl of the supernatant containing somatic cell DNA 
was aliquoted into a screw top Eppendorf tube and the remaining supernatant discarded. To 
prepare the sperm DNA, the pellet was resuspended in 2ml reagent B (Nucleon Biosciences) 
with p-mercaptoethanol and incubated at 37°C in a water bath for 1 hour. 500(0.1 of 5M 
sodium perchlorate was added, the tubes placed on a blood tube rotator (Stuart Scientific) and 
spun for 15 minutes at room temperature. The samples were then incubated at 65°C while 
shaking. 2ml of chloroform was added and spun on the blood tube rotator for a further 10 
minutes. The samples were spun at 800 g for 1 minute, 300jli1 of resin (Nucleon Biosciences) 
added, mixed by inversion and centrifuged at 1400 g for 3 minutes. 2ml of the upper layer 
was transferred to a fresh 15ml tube, avoiding the resin. 2.5 x volume 100% ethanol was 
added and the tubes inverted several times to precipitate the DNA. Following a pulse spin at
4.000 rpm in a bench top centrifuge for 30 seconds, the ethanol was removed and the pellet 
dissolved in 250JJ.1 TE. The dissolved sperm DNA was transferred to a fresh 1.5ml screw top 
Eppendorf and stored at -20°C.
To purify the somatic DNA from the SDS sensitive fraction, 500jil of buffered phenol was 
added and the two layers mixed well. The samples were spun at 14,000 rpm for 10 minutes in 
a bench top centrifuge and the top layer (approximately 500jil) transferred to a fresh 1.5ml 
screw top Eppendorf. Equal volume of phenol:chloroform:isoamylalcohol (25:24:1) was 
added and the two layers mixed well again. The samples were spun at 14,000 rpm for 10 
minutes in a bench top centrifuge and the upper layer transferred to a fresh 1.5ml screw top 
Eppendorf. 0.1 x volume of 2M Sodium Acetate and 2.5 x volume 100% ethanol were added 
and the tubes inverted several times to precipitate the somatic DNA. Following a pulse spin at
14.000 rpm for 30 seconds, the ethanol was removed and the pellet dissolved in 50(0.1 TE.
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2.1.3 Preparation of DNA from human tissue
In order to prepare DNA from a fixed tissue sample, the paraffin has to be removed. The 
following protocol was adapted from the Nucleon Biosciences BACC III genomic DNA 
extraction kit blood and cell culture protocol.
A 2cm3 block of paraffin embedded, formalin-fixed tumour tissue was thinly sliced and mixed 
in 20ml of xylene in a glass bijou on a blood tube rotator for 1 hour. The xylene was 
removed and the tissue placed in a 1.5ml screw top Eppendorf containing 550pl lysis buffer 
and 15|iil 20mg/ml proteinase K. The sample was incubated overnight at 60°C in a water bath.
Frozen tissue was thawed at room temperature and 10-20mg minced. The tissue was placed 
in a 1.5ml screw top Eppendorf containing 550jil lysis buffer and 15pi 20mg/ml proteinase K 
and incubated overnight at 60°C in a water bath. All samples were centrifuged at 4,000 rpm 
for 1 minute in a bench top centrifuge and 250pl of the supernatant transferred to a fresh 
1.5ml screw top Eppendorf. lOOpl of de-ionised water was added and the samples vortexed 
for 5 seconds. 150pl of 5M sodium perchlorate was added and the tubes inverted at least 
seven times. 600pl of chloroform was added and the tubes inverted seven times. 150pl of 
resin was added and the tubes rotary mixed for 5 minutes. The samples were centrifuged at 
500 g for 2 minutes. The upper layer was transferred to a fresh 1.5ml screw top Eppendorf, 
avoiding the resin interface. 1.2ml of 100% ethanol was added and the tubes inverted several 
times until the DNA precipitated. The samples were centrifuged at 14,000 rpm for 5 minutes 
in a bench top centrifuge and the supernatant discarded. 1ml of cold 80% ethanol was added 
and the tubes inverted several times. The samples were centrifuged at 14,000 rpm for 5 
minutes in a bench top centrifuge and the supernatant discarded. The DNA pellets were 
dissolved in 100-200}il TE and heated at 60°C for 1 hour. DNA was stored at -20°C.
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2.2 PCR Allele Typing
2.2.1 CTG18.1
Samples prepared in section 2.1.1 and 2.1.3 were thawed at room temperature. 5ng of DNA 
was amplified in lOpl reactions using lx PCR buffer, lpM  forward primer SEF2-C, lpM 
reverse primer SEF2-BR and 0.05 U/pl Taq Polymerase (Amplitaq, Perkin Elmer) in 0.2ml 
thin-walled tubes. Reactions were cycled through 30 rounds of 96°C (45 seconds), 67°C (45 
seconds) and 70°C (3 minutes) and one further cycle of 67°C (1 minute) and 70°C (10 
minutes) in a Biometra UNO I I 96 thermocycler. 3pl of Orange G loading dye was added 
and the reaction products separated by electrophoresis through a 2% NuSieve GTG Low 
melting temperature agarose (Flowgen)/l% Agarose (BM) 20cm gel in 0.5 x TBE buffer at 
150 volts for 90 minutes. 600ng of lkbp Ladder (GibcoBRL) was electrophoresed down 
each side of the gels. PCR products were visualised on a UV transilluminator (UVP Ltd), 
captured with a UVP digital camera and photographs printed on Kodak thermal paper.
2.2.2 CTG18.1 fluorescent typing
Samples prepared in section 2.1.1 were thawed at room temperature. 5ng of DNA was 
amplified in lOpl reactions using lx PCR buffer, lpM fluorescent forward primer SEF2-C-F, 
lpM reverse primer SEF2-BR and 0.05 U/pi Taq Polymerase (Amplitaq, Perkin Elmer) in 
0.2ml thin-walled tubes. Reactions were cycled through 28 rounds of 96°C (45 seconds), 
67°C (45 seconds) and 70°C (3 minutes) and one further cycle of 67°C (1 minute) and 70°C 
(10 minutes) in a Biometra UNO I I 96 thermocycler. 2jal of the reaction products was 
transferred to a fresh 0.2ml thin-walled tube, removing any excess oil from the tip before 
transferring, lul of GeneScan standard mix was added in order to mix the molecular weight 
standard with the PCR products and the samples denatured at 90°C for 2 minutes in a 
Biometra UNO I I 96 thermocycler. Following a brief spin in a bench top centrifuge, samples 
were electrophoresed through a 4.75% urea polyacrylamide gel in a 373XL automated 
sequencing machine (Perkin Elmer) for 5-12 hours on Filter Set A at 40 watts, depending on 
the size of the alleles. The resulting Gel File was analysed with GeneScan software version
3.1 (Perkin Elmer).
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2.2.3 ERDA1
Samples prepared in section 2.1.1 and 2.1.3 were thawed at room temperature and underwent 
typing PCR at the ERDA1 locus in an identical way to the CTG18.1 locus. Primers ERDA-C 
and ERDA-DR were substituted for primers SEF2-C and SEF2-BR and the annealing 
temperature was 62°C.
2.2.4 ERDA1 fluorescent typing
Samples prepared in section 2.1.1 and 2.1.3 were thawed at room temperature and underwent 
fluorescent typing PCR at the ERDA1 locus in an identical way to the CTG18.1 locus. 
Primers ERDA-A-F and ERDA-DR were substituted for primers SEF2-C-F and SEF2-BR 
and the annealing temperature was 62°C.
2.2.5 ERDA1 A/C polymorphism typing
Chimpanzee DNA and samples prepared in section 2.1.1 were thawed at room temperature 
and underwent typing PCR at the ERDA1 locus in an identical way to Section 2.2.3. Primers 
ERDA-ERG or ERDA-ERT were separately substituted for primer ERDA-DR in identical 
reactions with a 62°C annealing temperature.
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2.3 SP-PCR
DNA samples from sperm as prepared in section 2.1.2 and from blood, tumours and cell lines 
supplied by Dr. Tetsuo Ashizawa, Dr. Robert Brown, Prof Patricia Jacobs and Dr. Anne 
Murray, Dr. Marvin Meistrich, Dr. Michael Siciliano, Dr. Margot Thomas and Centre 
d’Etude du Polymorphisme Humain (CEPH) were digested with HindUI and diluted in 
lOmM Tris-HCl pH 7.5, lmM EDTA and O.ljiM carrier forward primer (to combat reduction 
of genomic DNA concentration during storage). 12pg - 50 ng of HindUI digested DNA was 
amplified in 7pl reactions using 1 x PCR buffer, 0.2jiM forward primer, 0.2pM reverse 
primer (Table 2.1) and 0.05 U/pi of Taq Polymerase (Amplitaq, Perkin Elmer). Reactions 
were cycled through 28 rounds of 96°C (45 seconds), 55-68°C (45 seconds) and 70°C (3 
minutes) and one further cycle of 55-68°C (1 minute) and 70°C (10 minutes) in a Biometra 
UNO I I 96 thermocycler. 4.2pi of the reaction products were electrophoresed through a 
1.75% 20cm agarose gel in 0.5 x TBE buffer at 90 volts for 17 hours, lpg each of Amplisize 
and 2.5kb ladder molecular weight markers (BioRad) respectively were electrophoresed along 
the side and down the middle of each gel. Gels were Southern blotted overnight and 
hybridised with 20ng of a CTG repeat probe and 6.7ng of each of the Amplisize and 2.5kb 
ladder (Section 2.5). Resultant alleles were detected by autoradiography (16h-7days) with 
exposure to an intensifying screen at room temperature.
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2.4 Single molecule fluorescent PCR
0.7pl of the single molecule reaction products from Section 2.3 were diluted 1:100 in de­
ionised water and ljil re-amplified in 10|il reactions using 1 x PCR Buffer, 0.2jliM forward 
FAM fluorescent primer (Oswell), 0.2|iM reverse primer and 0.05 U/|Lil of Amplitaq. 
Reactions were cycled through 19 rounds of 96°C (45 seconds), 57 °C (ERDA1) or 62°C 
(CTG18.1) (45 seconds) and 70°C (3 minutes) and a chase of 57 °C (ERDA1) or 62°C 
(CTG18.1) (1 minute) and 70°C (10 minutes) in a Biometra UNO II 96 thermocycler. 
Reaction products were electrophoresed on a 4.75% polyacrylamide gel as previously 
described in Section 2.2.2 and analysed with Genescan 3.1 software.
Primer Name Sequence (5’-3’)
DM-A (Forward)
DM-BR (Reverse)
DM-C (Forward)
DM-C-F (Fluorescent Forward) 
ERDA-A (Forward)
ERDA-A-F (Fluorescent Forward) 
ERDA-BR (Reverse)
ERDA-C (Forward)
ERDA-DR (Reverse)
ERDA-ERG (Reverse) 
ERDA-ERT (Forward)
SBMA-F (Forward)
SBMA-R (Reverse)
SCA1-F (Forward)
SCA1-R (Reverse)
SEF2-BR (Reverse)
SEF2-C (Forward)
SEF2-C-F (Fluorescent Forward)
CAGTTCACAACCGCTCCGAGC
CGTGGAGGATGGAACACGGAC
AACGGGGC TCGAAGGGTC C T
FAM-SPACER-AACGGGGCTCGAAGGGTCCT
CTATCAATGGCTCCAAGTAGCAC
FAM-SPACER-CTATCAATG G CTCCAAG TAG CAC
ATCCTTTTGCAACTAGCGGTGAC
GGAAGGCATCTTCAAAATGGATTG
GAAAAATAAGGTGGAAGGAAGGTC
ATAAGGTGGAAGGAAGGTCTTTTG
ATAAGGTGGAAGGAAGGTC T T T T T
GC C TGTTGAAC TC TTC  TGAGC
GAGGAACAGCAACCTTCACAGC
CAACATGGGCAGTCTGAG
CTCAGACTGCCCATGTTG
AGGAACGAATGGAGAAAGTGCAAC
AATCCAAACCGCCTTCCAAGTG
FAM-SPACER-AATCCAAACCGCCTTCCAAGTG
Table 2.1 Sequences of PCR primers. Depicted are the primer sequences used in typing, 
fluorescent and SP-PCR. FAM is the blue fluorescent tag 6-carboxyfluorescein. The spacer 
is comprised of a random six nucleotide sequence to facilitate the fluorescent primer binding.
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2.5 Southern blot hybridisation
Agarose gels were submerged in Depurinating Solution for 10 minutes, rinsed with de-ionised 
water then submerged in Denaturing Solution for 30 minutes. Gels were rinsed with de­
ionised water then submerged in Neutralising Solution for 30 minutes. Hybond-N nylon 
membrane (Amersham) equilibrated in Neutralising Solution was placed onto the gel which 
was laid on a flat surface. Squash blotting was set up by stacking equilibrated Whatman 
3MM paper, dry absorbant paper, a glass plate and a 2Kg weight sequentially on top of the 
gel. Transfer of DNA from the gel then took place overnight at room temperature. DNA was 
fixed to the membrane by baking at 80°C for 3 hours, followed by exposure to ultraviolet light 
(UVP transilluminator) for 20 seconds.
20ng of a (CTG)56 repeat PCR product and 6.7ng of each of the Amplisize (BioRad) and 
2.5kb ladder (BioRad) molecular weight markers in 32pl final volume were denatured at 
100°C for 5 minutes, quenched on ice and lOjil OLB (Oligo Labelling Buffer), 2pl 1 mg/ml 
BSA, 5|il a 32PdCTP (3000 Ci/mmole) and 2U Klenow (GibcoBRL) added. The labelling 
reaction was incubated at 37°C for 1 hour. A 1ml Sephadex G-50 column was prepared in a 
15ml falcon tube with polymer wool (Interpet) (acting as a plug) and 4% (w/v) Sephadex G- 
50 in TE. The sephadex was compacted by centrifugation at 2,000 rpm for 2 minutes. The 
probe was added to the column and centrifuged a second time at 2,000 rpm for 2 minutes to 
elute the probe into a 1.5ml Eppendorf tube. Purified probe was denatured at 100°C for 5 
minutes immediately prior to use.
Membranes were placed in a hybridisation bottle with 30ml of Hybridisation Solution and 
rotated at 65°C for a minimum of 1 hour. The probe was incubated with the membrane at 
65°C overnight in 3ml fresh Hybridisation Solution in a Biometra rotating hybridisation oven. 
Filters were washed twice at high stringency using Wash Solution at 65°C rotating. The 
filters were dried at 80°C and exposed to X-Ray film (GRI) in the presence of an intensifying 
screen (GRI) at room temperature. Autoradiographs were developed initially after overnight 
exposure and subsequently after 16 hours to 7 days.
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2.6 Reagents
lx  SSC
NaCl 0.15M
Tri-S odium Citrate 0.15 M
lx  TBE buffer
Tris 0.09M
Boric Acid 0.09M
EDTA pH 8.0 0.002M
lx  PCR Buffer
Tris HC1 pH 8.8 45mM
(NH4)2S 0 4 llmM
MgCl2 4.5mM
P-Mercaptoethanol 6.7mM
EDTA 4.4|aM
Deoxyadenosine triphosphate ImM
Deoxycytidine triphosphate ImM
Deoxyguanosine triphosphate ImM
Deoxythymidine triphosphate ImM
BSA 113 |J.g/ml
50x Te
Tris HC1 pH 7.5 0.5M
EDTA pH 8.0 5mM
Blue Loading Dye
Glycerol 50% (v/v)
5 x TBE 50% (v/v)
Bromophenol Blue 2pg/ml
Xylene Cyanol 2p,g/ml
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Denaturing Solution
NaCl
NaOH
Depurinating Solution
HC1
GeneScan standard mix
Formamide
Blue Loading Dye (Perkin Elmer)
Flourescent MW Standard GS2500 ROX (Perkin Elmer)
Hybridisation Solution
EDTA
SDS
Sodium Phosphate pH7.2
Lysis Buffer
Tris HC1 pH 8.0 
EDTA pH 8.0 
SDS
Neutralising Solution
Tris
NaCl
pH to 7.5 with concentrated HC1
0.5M
0.4M
0.25M
4.64:1:1.08 (v/v)
ImM 
7% (w/v) 
0.5M
50mM 
lOOmM 
0.5% (w/v)
0.5M
3.0M
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Oligo Labelling Buffer (OLB)
TE
Random Hexamers 
Hepes pH 6.6 
p-Mercaptoethanol 
Deoxyadenosine triphosphate 
Deoxycytidine triphosphate 
Deoxyguanosine triphosphate 
Deoxythymidine triphosphate 
Tris-HCl pH 8.0 
MgCl2
Orange G Loading Dye
Orange G Powder 
Glycerol 
de-ionised H20
TE
Tris HC1 pH 7.5 
EDTA pH 8.0
Wash Solution
SDS
SSC
30% (v/v)
30 OD units/ml 
1M
0.35% (v/v)
O.lmM
O.lmM
O.lmM
O.lmM
0.24M
2.4mM
0.6pg/ml 
50% (v/v) 
50% (v/v)
lOmM
ImM
0.2% (w/v) 
0.2x (v/v)
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2.7 Abbreviations
%GC Percentage of Guanosine and Cytidine
nucleotides in a DNA sequence 
bp Base pairs
BSA Bovine Serum Albumin
DNA Deoxyribonucleic acid
EDTA Ethylenediaminetetraacetic acid
FAM 6-carboxyfluorescein
kbp Kilobase pairs
Ln Natural Log
LOH Loss of heterozygosity
MMR Mismatch repair
MSI Microsatellite instability
NIX Nucleotide Identification package
No. Number
PCR Polymerase chain reaction
ROX 6-carboxy-x-rhodamine
rpm Revolutions per minute
Rpts Repeats
SDS S odium Dodecy 1 S ulfate
T ris Tris(hydroxymethyl)aminomethane
UTR Untranslated Region
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Chapter 3
Allele length diversity at the CTG18.1 and ERDA1 loci in the general population
3.1 Introduction
Since the discovery of dynamic mutations giving rise to inherited diseases, much work has 
focused on the somatic and germline behaviour of these trinucleotide repeats which has 
defined certain differences dependent on the sequence and its purity, location in respect to the 
gene and the length of the alleles. Expandable trinucleotide repeats give rise to diseases such 
as HD, SBMA and the spinocerebellar ataxias and in cases such as DM-1, have been 
documented to attain greater than 2,000 repeats in length in congenitally affected individuals. 
Recent collated data demonstrates that the trinucleotide diseases do have differing rates of 
mutability, with some evidence that high GC content in the flanking sequence and the 
proximity of CpG islands could be a major contributor (Brock et al., 1999). Recently two 
novel, expandable trinucleotide repeats were discovered on chromosomes 17q21.3 and 
18q21.1, termed ERDA1 and CTG18.1. These loci are not yet associated with a disease but 
have a greater frequency of expanded alleles than any of the previously characterised loci.
This makes them ideal candidates on which to observe how repeat loci can be affected by 
factors such as flanking sequence, inherited mutations in MMR genes and external 
environmental influences.
3.2 Results
Semen samples collected from an infertility clinic and blood samples from DM-1 or HNPCC 
patients were lysed and PCR performed across the polymorphic repeats at the CTG18.1 and 
ERDA1 loci. Crude DNA was prepared by a simple lysis procedure (Section 2.1.1) and PCR 
was carried out using primers SEF2-C/BR (Section 2.2.1) or ERDA1-C/DR (Section 2.2.3). 
The PCR products were electrophoresed through a 2% NuSieve GTG Low melting 
temperature agarose/1% Agarose TBE gel and visualised on an UV transilluminator (Figures
3.1 and 3.2). Shown in Figures 3.1 and 3.2 are examples of typing in either blood or sperm 
DNA. 628 and 616 chromosomes were typed at the CTG18.1 and ERDA1 loci respectively in 
the semen samples in order to select candidates for SP-PCR analysis and to provide allele 
distributions for each locus. Products ranging from 10-91 repeats and 7-82 repeats were 
observed at the CTG18.1 and ERDA1 loci respectively. Samples where only one allele was
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detected were checked for homozygosity by PCR Southern blot (not shown). No samples 
demonstrated a second allele at either locus.
The agarose gels gave an approximation of allele sizes. Consequently, PCR was repeated at 
both loci utilising a fluorescently tagged forward primer (Sections 2.2.2 and 2.2.4) and the 
products electrophoresed through a 4.75% denaturing urea polyacrylamide gel in a 373XL 
automated sequencing machine. Sample data was analysed using GeneScan 3.1 software 
following visualisation (Figures 3.3 and 3.4). The GeneScan software is capable of sizing 
PCR products to within a base pair due to internal fluorescent molecular weight size standards 
run with the PCR product in each lane of the urea polyacrylamide gel. The fluorescent size 
standard is detected as Red, whereas PCR products can be detected as Blue, Green or Yellow 
depending on the fluorescent tag. In this case, products were labelled with a FAM tag, 
detected as Blue on Filter Set A. The peak with the greatest area was used to type each 
chromosome (Figure 3.5) and the total frequencies of each allele plotted for each locus 
(Figures 3.6 and 3.7).
3.3 Discussion
The allele range of 10-91 repeats at the CTG18.1 locus fits well with published data by 
(Breschel et a l, 1997). The most common alleles are 11 repeats (34.6%), 14 repeats (16.1%) 
and 17 repeats (14%) and an expansion (>50 repeats) frequency of 2.9%. The allele range at 
the ERDA1 locus also correlates well with published data from Nakamoto et a l, (1997), 
Ikeuchi et a l, (1998) and Deka et al, (1999). The most common alleles are 10 repeats 
(31.5%), 21 repeats (17.1%) and 22 repeats (12.4%) and an expanded allele frequency of 
15.1%. Both loci seem to display trimodal distributions. CTG18.1 demonstrates groups of 
alleles from 10-18, 19-41 and 60-91 repeats, with no detectable alleles between 41 and 60 
repeats. ERDA1 displays groups of alleles from 7-11, 13-29 and 49-82 repeats with only two 
intermediate alleles of 36 and 44 repeats detected.
The distribution of alleles at these two loci would seem to infer that the ERDA1 locus is more 
stable than the CTG18.1 locus. Comparison of the frequencies of similarly sized alleles 
would suggest that the original allele sizes of 11 and 10 repeats at CTG18.1 and ERDA1 
respectively, underwent rare expansion events to larger alleles of 14 and 17, and 17 and 21 
repeats. It is possible that these larger alleles have undergone more common mutations of 
small length changes, likely to be due to their increase in size and contributed to the spread of 
alleles in the normal range. Extrapolating on this point it is also possible that the pool of 
alleles from 50-100 repeats at either locus derived from a rare expansion originating within its
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individual 20-40 repeat range. ERDA1 has an increased frequency of alleles in the 50-90 
repeat range which suggests that these alleles are more stable and maintain their frequency in 
the human population. This is supported by the detection of extremely large CTG18.1 alleles 
(Breschel et a l, 1997) suggesting that this locus has the potential to produce huge expansions 
that have so far not been detected at the ERDA1 locus.
The increase in extra bands detected in the PCR products with increasing repeat length 
(normally seen as a smear) indicates there may also be instability in the DNA typed. Using 
small quantities of DNA in PCR reactions at other loci such as DM-1 and SCA7 has 
demonstrated that this smear can be resolved into multiple bands. PCR products from the 
ERDA1 locus possess tighter bands than equivalent sized alleles at CTG18.1 on both agarose 
and polyacrylamide gels, further suggesting that the CTG18.1 locus could be more unstable 
than the ERDA1 locus.
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Figure 3.1 Allele typing at the CTG18.1 locus. Each typing reaction was carried out with 
primers SEF2-C/BR. Control PCR on genomic DNA DAMO (11,11) and GOM C (11,17) was 
also carried out for approximation of allele sizes and on a zero DNA control. PCR products 
were electrophoresed through a 2% NuSieve/1%  Agarose gel and visualised on a UV 
transilluminator. Allele sizes in repeats are depicted for each sample and 1Kb ladder loaded in 
the m arker lane (M).
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Figure 3.2 Allele typing at the ERDA1  locus. Each typing reaction was carried out with 
prim ers ERDA-C/DR. Control PCR on genomic DNA DAM O (19,62) and GOM C (22,60) 
was also carried out for approximation o f allele sizes and on a zero DNA control. PCR 
products were electrophoresed through a 2% NuSieve/1%  Agarose gel and visualised on a 
UV transilluminator. Allele sizes in repeats are depicted for each sample and 1Kb ladder 
loaded in the marker lane (M).
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Figure 3.3 Fluorescent allele typing at the CTG18.J locus. Each typing reaction was 
carried out w ith primers SEF2-C-F/BR. Control PCR on genom ic DNA DAMO (11,11) 
and GOMC (11,17) was also carried out for approxim ation o f allele sizes and on a zero 
DNA control. PCR products were electrophoresed through a 4.75%  urea polyacrylam ide 
gel and analysed with GeneScan 3.1 software. GS2500 ROX standard is depicted red, 
PCR products are blue.
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Figure 3.4 Fluorescent allele typing at the E R D AI locus. Each typing reaction w as 
carried out w ith primers ERDA-A-F/DR. Control PCR on genom ic DNA DAM O (19,62) 
and GOM C (22,60) was also carried out for approxim ation o f allele sizes and on a zero 
DNA control. PCR products were electrophoresed through a 4.75%  urea polyacrylam ide 
gel and analysed w ith GeneScan 3.1 software. GS2500 ROX standard is depicted red, 
PCR products arc blue.
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Figure 3.5 GeneScan profiles of E R D A l fluorescent PCR products. G eneScan analysis of 
fluorescent PCR products electrophoresed on an automated sequencing m achine produced 
separate prof iles for each sample. The PCR product is depicted blue and the GS25(X)ROX 
standard depicted red. The fluorescence is detected as a peak and the si/.e o f the product 
recorded in bp which is converted to repeats. Sizes of the alleles in repeats is depicted.
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Chapter 4
Male germline repeat behaviour at the CTG18.1 and ERDA1 loci
4.1 Introduction
Typing of individuals from affected families of trinucleotide repeat diseases explained the 
phenomenon of anticipation occurring in transmission. Adaptation of the SP-PCR technique 
to microsatellite loci, predominantly the DM-1 locus, then allowed the precise and differing 
behaviour of these repeats to be identified (Monckton et al, 1995, Martorell et a l, 1998, 
Monckton et a l, 1999). Huge alterations in repeat size with a bias toward expansions could 
be observed at the DM-1 locus in the sperm of even asymptomatic individuals, whereas the 
blood DNA from the same individual is relatively stable (Monckton et a l, 1995). Muscle also 
showed large CTG expansions at the DM-1 locus that correlated with the disease phenotype 
(Monckton etal ,  1995).
Recent comparisons of the relative stability of the various CAG/CTG trinucleotide repeats in 
transmission suggests that flanking sequence is a major contributor (Brock et al,  1999). A 
positive correlation was found between increasing %GC content in the flanking sequence and 
expandability. The limited data available for ERDA1 suggests it has the lowest expandability 
in male transmission, whereas HD, SCA2, SCA7 and DM-1 have high expandabilities 
correlating with high %GC content. For this reason, we sought to further define the behaviour 
at the ERDA1 locus and generate data for the CTG18.1 locus in the male germline and to 
compare this with data from other trinucleotide repeat loci utilising the sensitive SP-PCR 
technique.
4.2 Results
4.2.1 SP-PCR at the CTG18.1 and ERDA1 loci
Following typing of male semen donors at the CTG18.1 and ERDA1 loci (Section 2.2), 
candidates were selected to provide a broad range of data comprising normal and expanded 
alleles. Good quality sperm DNA was isolated, restriction digested and a preliminary SP- 
PCR was carried out at either CTG 18.1 or ERDA1 (Section 2.3) on a range of concentrations 
in order to optimise the SP-PCR reactions for approximately 1 and 100 molecules per
54
reaction (Figure 4.1). The purpose was to observe any frequent small length changes (<5 
repeats) at the single molecule level and rarer, large length changes (>5 repeats) occurring at 
the level of 100 molecules per SP-PCR reaction. Reactions were scored positive according to 
whether a lane displayed one or more bands at the low concentration, separately for each 
allele. From the preliminary SP-PCR, 8 reactions of the low concentration were scored and 
the frequency of negative reactions (p(0)) was calculated as :
total-positive/total
The number of molecules observed at this concentration of DNA per SP-PCR reaction, was 
calculated by applying p(0) to the equation derived from the Poisson distribution:
no. molecules per reaction = -In p(0)
This value indicates the approximate number of molecules on average per reaction at this 
concentration of DNA for a given allele. Therefore, the concentration of DNA needed for 1 
molecule and 100 molecules per reaction can be calculated and an increased number of 
reactions carried out to observe any rare, large length changes. From these blots, a more 
accurate value was calculated for the number of molecules analysed and the mutation rate and 
average length change was then estimated. It was also important to monitor contamination and 
so 32 negative DNA SP-PCR reactions were carried out with the same reagents as the sperm 
DNA samples. Each set of reactions was only included for analysis if no contamination was 
detected.
Blood DNA was not available to estimate the progenitor allele sizes of the male donors, so 
DNA from the somatic cell fraction of the sperm lysis protocol was isolated (Section 2.1.2) 
and fluorescent PCR carried out in order to type these individuals (Sections 2.2.2 and 2.2.4). 
A total of 15 semen samples underwent SP-PCR analysis at the CTG18.1 locus (Table 4.1) 
and 8 at the ERDA1 locus (Table 4.2). An average of 7,890 sperm were analysed per allele, 
per individual for large concentration SP-PCR. Examples of large scale CTG18.1 SP-PCR 
with low concentration DNA (Figure 4.2) and high concentration DNA are displayed (Figure 
4.3). Normal alleles less than 50 repeats at the CTG18.1 locus have low but detectable large 
length change mutation rates of 0-0.02%. The two mutations that were detected were 
expansions of 11 and 15 repeats from 35 and 38 repeat alleles respectively. A moderately 
expanded allele of 60 repeats had two expansions of 6 and 9 repeats, and thus a mutation rate 
of 0.02%. Alleles of 70-80 repeats had mutation rates of 0.22-0.73% for large length changes 
and 80-91 repeat alleles, 0.04-1.57%. The alleles in the 80-91 repeat range are variable as an 
84 repeat had a very low mutation rate of 0.04% and an 87 repeat (GS12) had a much higher
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mutation rate than a 91 repeat (1.57% and 0.52% respectively). The average length changes 
for these large mutations suggest that the normal and moderately expanded alleles increase by 
0.002 repeats per sperm and the large alleles have an increasing number of contractions and 
expansions with increasing repeat length resulting in average length changes ranging from 
-0.052 to +0.592 (87 repeat of GS12). Therefore the combination of increased mutation rate 
and average length change of the 87 repeat would suggest that some other cis or trans-acting 
factor could be contributing to its increased instability.
Figure 4.4 depicts low and high concentration SP-PCR at the ERDA1 locus in three different 
samples with increasing upper allele sizes. The ERDA1 locus is much more stable than the 
CTG18.1 locus and large length changes are rare. Normal alleles less than 50 repeats are very 
stable, although one expansion of 25 repeats was observed from a 29 repeat allele (mutation 
rate 0.01% (Table 4.2)). Only three other large length changes were observed in the 
remaining samples, expansions of 23 and 34 repeats from the 59 repeat allele and 28 repeats 
from the 67 repeat allele (mutation rates of 0.02% for both alleles). No conclusions can be 
drawn from the average length changes due to the small number of samples that showed 
mutations. Sample GS12 is the only sperm sample to be analysed at both loci. Its 87 repeat 
at the CTG18.1 locus has a higher mutation rate and increased average length change for large 
length mutations, and its 67 repeat at the ERDA1 locus is one of only two expanded alleles 
that demonstrate mutations. Therefore it seems possible that there is some other factor that 
could be contributing to increased instability at the CTG18.1 and ERDA1 loci in this sample.
4.2.2 Single molecule fluorescent PCR at the CTG18.1 and ERDA1 loci
SP-PCR analysis provides a generalised picture of the behaviour of repeats but small length 
changes are difficult to measure accurately. Therefore by utilising GeneScan analysis which 
allows accurate sizing of differences between alleles in the same sample, mutation rates and 
average length changes can be calculated exactly. First round SP-PCR reactions of low 
concentration DNA were diluted 1:100 and cycled through a second round PCR reaction 
incorporating a fluorescent forward primer. PCR products were run on a 4.75% 
polyacrylamide gel with GS2500 ROX standard and analysed with GeneScan 3.1 software.
On average, 117 molecules per allele were analysed, the peak with the greatest area taken to 
indicate allele size.
Figures 4.5 and 4.6 depict examples of GeneScan gels with second round single molecule 
PCR products at either the CTG18.1 or ERDA1 loci. PCR products are blue and size 
standard red. The lower alleles are stable, displayed as a clear sharp band. The upper alleles 
however, have broader profiles made up of multiple bands that increase with increasing allele
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length. These extra bands that accompany the main band are PCR artefacts called “stutter” 
and mainly precede, but sometimes are larger in size than the main PCR product. Analysis of 
the profile of each lane (and hence reaction) means negative PCR reactions can be clearly 
scored and the presence of greater than one allele can be easily detected (Figure 4.7). As 
depicted in Figure 4.7, a single molecule will produce a peak with a series of progressively 
smaller peaks preceding it. However, if any peak preceding the largest peak has a larger 
height than expected of stutter, this is also classed as a real peak. Figures 4.5 demonstrates 
how increasing allele size leads to increasing mutation rate at the CTG18.1 locus. The 
majority of allele length changes are within 1 repeat in sample GS153 (11, 38) but an 
expansion of 6 repeats can be seen in the final lane. Sample GS 166 (11, 71) however has a 
larger upper allele and hence changes of 1-2 repeats are more common. The frequencies of 
these alleles are represented in Figure 4.8 which shows how increasing repeat length leads to 
an increasing spread of alleles within the population of sperm. Figure 4.6 shows the same 
behaviour at the ERDA1 locus. Sample GS174 has allele sizes of (16, 29) and no changes can 
be observed in 106 molecules analysed. Sample GS110 has larger alleles of (10, 74) and the 
upper allele can be seen to be moderately unstable with frequent changes of 1-2 repeats, and 
deletions of 4 and 5 repeats are evident.
By measuring the frequency of mutations at these two loci in various semen samples, mutation 
rates and average length change were calculated. Firstly the number of molecules analysed 
was calculated for each allele in the sample based on the observations on the GeneScan gel. 
The total number of observed positives for each allele was divided by the total number of 
observed positives analysed, then multiplied by its difference from the progenitor allele (+/-) 
to give an average length change, in repeats. Displayed in Tables 4.1 and 4.2 are the number 
of molecules per reaction, total number of molecules analysed, mutation rate and average 
length change for both alleles of each sample analysed at the single molecule level.
The mutation rates and average length changes at both loci are displayed in Figures 4.9,4.10, 
4.11, and 4.12. Figure 4.9 is a scatter graph depicting the mutation rates of alleles at the 
CTG18.1 locus from 11 to 91 repeats in length. There is clearly an increasing mutation rate 
with increasing allele length, displayed as a sigmoidal curve. Alleles of 11-17 repeats are very 
stable with no mutations, alleles less than 36 repeats have increased mutation rates of between 
3 and 24 % and alleles from 67-91 repeats have elevated mutation rates of between 75 and 
89%. 95% confidence intervals for the mutation rate, taking into account 95% confidence 
intervals for the number of sperm analysed, are also plotted for each allele where possible. 
Plotting the average length change at the CTG18.1 locus demonstrates that as the alleles 
increase in length, they do not necessarily expand (Figure 4.10). In fact, the majority of 
alleles are contracting. Alleles less than 40 repeats, which can have mutation rates of up to
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24%, seem to have relatively equal numbers of expansions and contractions and hence have 
only moderate overall contraction rates. Alleles from 67-91 repeats on the whole tend to 
contract by up to two repeats on average. The alleles from 60-71 repeats have low average 
length changes, either positive or negative, which could help to explain why 40-60 repeats are 
so rare in the samples typed. There is a greater probability that mutations would be less than 
5 repeats and so new alleles would remain within the same range. The 87 repeat has an 
unusually large positive average length change compared to the other alleles in this repeat 
range, confirming the large length data from the same sample and increasing the positive 
average length change (Table 4.1).
The mutation rates of ERDA1 alleles are displayed in Figure 4.11. Although there are a 
decreased number of alleles analysed at this locus, there is a clear difference from the 
CTG 18.1 locus. The alleles are more stable, with alleles of equivalent length possessing lower 
mutation rates. Whereas at the CTG18.1 locus alleles of 20-30 repeats are mutating, at the 
ERDA1 locus alleles are stable until the 30-40 repeat range. Again there is a lack of alleles 
available between 40-50 repeats, but alleles of 81 repeats have a mutation rate as low as 59%. 
At the CTG18.1 locus, an equivalently sized allele would have a mutation rate of 
approximately 80%. The average length change at this locus is plotted in Figure 4.12. The 
mutation rate demonstrates that this locus is particularly stable and so any large changes 
would be unexpected. The greatest average length change was in fact from the largest allele of 
81 repeats, but still only moderate at -0.6 repeats per sperm. All alleles that did mutate did so 
with a bias toward contractions at this locus.
To address the question of meiotic drive at the CTG18.1 and ERDA1 loci, the single molecule 
observations of each sample underwent a Chi-squared test and no significant difference was 
found between the number of positives for each allele, i.e. there are equal numbers of the 
small versus the large allele in each sample.
4.3 Discussion
Direct comparison of the two loci, CTG 18.1 and ERDA1, with each other and the DM-1 locus, 
demonstrates that the same sequence of repeat can behave very differently. Single molecule 
data from the DM-1 locus which also has an expandable CTG repeat (Appendix 2) shows a 
particularly unstable locus heavily biased toward expansion in the male germline. Mutation 
frequencies become measurable in the mid 20 repeat range with a mixture of expansions and 
contractions until the alleles reach approximately 30 repeats in length. Then the alleles start to 
expand much more frequently until they reach approximately 35 repeats whereby they achieve
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mutation rates of 60%. SP-PCR analysis at this locus demonstrates that alleles greater than 
50 repeats (defined as expansion alleles) have essentially a 100% mutation rate, 99% biased 
toward expansions (Monckton et a l, 1995).
CTG 18.1 and ERDA1 however seem to be more stable than the DM-1 locus, but still possess 
underlying mutation rates of detectable levels. SP-PCR analysis demonstrates that large 
length changes are rare at CTG 18.1 even with large alleles of up to 91 repeats and even less 
evident at the ERDA1 locus. Again, at the single molecule level, GeneScan analysis confirms 
that CTG 18.1 has a lower mutation rate than DM-1 and a higher mutation rate than ERDA1.
In fact, all three loci demonstrate the pattern of increasing mutation rates with increasing allele 
length, but the nature of these mutations is what makes these loci distinct. DM-1 has a heavy 
bias toward expansions, 30-40 repeat alleles mutating at up to 60% frequency, leading to the 
disease alleles (>50 repeats) giving rise to the DM phenotype. The DM-1 CTG repeat is 
located in the 3’ UTR of the DM-7PK gene and the putative promoter of the Six5 gene. The 
flanking sequence of this repeat is high in %GC content and also within the CpG island for 
Six5. The CTG18.1 CTG repeat is located in the third intron of the SEF2-1 gene which has a 
lower flanking GC content and a lack of extensive human genomic sequence for the SEF2-1 
gene means that the location, if any, of a CpG island is yet to be determined and related to the 
instability of the CTG repeat. The ERDA1 locus has been sequenced in a BAC clone and 
NIX analysis (Williams et al., 1998) suggests it is not located within a gene. The fact that the 
mutation rate declines from DM-1 to CTG18.1 to ERDA1, with an increasing tendency toward 
contraction respectively is very likely to be linked to the decreasing GC content in the flanking 
sequence. The result is reflected in the distribution and frequency of alleles at these loci. The 
DM-1 locus has a similar distribution to the CTG18.1 locus, the most frequent allele being 5 
repeats at approximately 35% frequency. The frequency of expanded alleles (>50 repeats) is 
1 in 8000. The frequency of expanded CTG18.1 alleles is 3% and ERDA1 alleles 15%. The 
high level of ERDA1 expanded alleles available is most probably due to their stability. 
Expanded ERDA1 alleles have been demonstrated to possess a C polymorphism immediately 
3’ to the CTG repeat. This polymorphism has been confirmed in the samples analysed by 
utilising primers differing at the final 5’ nucleotide (Section 2.2.5). This allowed selective 
amplification of alleles possessing the A/C polymorphism and their associated repeat which 
could be separated by size by agarose gel electrophoresis. All alleles <50 repeats were found 
to have A 3’ to the CTG repeat and all alleles >50 repeats have C 3’ to the CTG repeat. 
Chimpanzee DNA has also been typed for this polymorphism in order to identify the 
ancestral variant. All the chimpanzee samples indicate small length ERDA1 alleles associated 
with the A variant. Therefore it is possible that mutation of this polymorphism from an A to a 
C could have predisposed a normal allele to a rare expansion, giving rise to the pool of larger 
alleles >50 repeats.
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Data available from 731 transmissions of the ERDA1 repeat suggests there is a contraction 
bias of expanded alleles in males and an expansion bias in females, with increasing mutation 
rate correlating with increasing allele size (Ikeuchi et al, 1998, Deka et a l, 1999). The SP- 
PCR and single molecule data confirms the observations in male transmissions, although the 
allele length difference is larger in the transmissions than the single sperm data would 
suggest. Contractions of up to 4 (Ikeuchi et a l, 1998) and 15 repeats (Deka et a l, 1999) have 
been observed in male transmissions whereas the largest average length change was of -0.582 
repeats (82 repeat allele). However, the single molecule data is effectively measuring the 
average length change of 6,951 transmissions from this 82 repeat allele (Table 4.1) which 
provides a more accurate representation of the behaviour of this repeat in the population as a 
whole. It would be interesting to accurately measure the mutation rates and average length 
changes in samples with larger alleles that naturally arise in a population such as the Chinese. 
The higher prevalence of large ERDA1 alleles in the Chinese could have arisen due to a 
bottleneck in the evolution of the population, or there may be a predisposition to a higher rate 
of expansion compared to Europeans.
CTG18.1 alleles are moderately unstable and though expansions are seen, overall there is a 
tendency toward contraction. Again, there seems to be two sets of alleles less than 100 
repeats, but the larger alleles tend to be a little less definite in whether they will expand or 
contract. These differences could be due to personal genetic differences in the individuals 
sampled, such as the 87 repeat from sample GS12, which seems to expand more frequently 
than the 91 repeat for both small and large length changes. Whether these differences are due 
to polymorphisms in the immediate flanking sequence or variants in other genes is not known, 
although immediate flanking polymorphisms are currently being investigated at the CTG 18.1 
locus. This more varied behaviour is likely to account for the pool of alleles between 60 and 
91 repeats and their persistent stable frequency. Large alleles at the DM-1 locus however are 
rare, again due to the fact that once these alleles are greater than 50 repeats, they expand 
rapidly within one generation and are lost through further size increases.
Comparison of the single molecule data for each sample found there was no significant 
difference in the numbers of small versus large alleles in the sperm of heterozygotes. This 
would suggest there is no evidence for meiotic drive in the male germline at the CTG 18.1 and 
ERDA1 loci.
Comparison of the single molecule data for the CTG18.1 and ERDA1 loci with other 
trinucleotide repeats suggests that ERDA1 is indeed very stable and CTG 18.1 is moderately 
unstable. The DM-1, HD, DRPLA, SBMA, SCA1 and MJD/SCA3 loci have higher mutation 
rates for equivalently sized alleles but the closest pattern of mutations is with MJD/SCA3
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which also demonstrates an increasing frequency of contractions with increasing allele length. 
MJD/SCA3 also has a lower %GC content, correlating with its lower expandability (Brock et 
al., 1999). The data for the two loci studied confirms that ERDA1 and CTG18.1 have the 
lowest expandability correlating with low %GC content in the flanking sequence of any of the 
CAG/CTG trinucleotide repeats.
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Figure 4.1 Preliminary SP-PCR at the CTG18.1 locus on sperm. Preliminary SP-PCR at the 
CTG 18.1 locus on sperm samples GS77 (14,60), GS273 (11,75), G S 131 (18,79), G S 12 (16,87). 
A m plisize/2.5K b marker (M) bands are labelled as equivalent sizes in repeats. M ols = molecules. 
Positive reactions can be scored and the number of molecules analysed calculated. Frequent small 
length changes can be observed at the single molecule level and increasing instability with increasing 
allele size.
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Figure 4.2 Large scale SP-PCR at the CTG18.1 locus on single molecule DNA isolated from 
sperm. Single molecule SP-PCR at the CTG18.1 locus on sperm samples G S66 (11,37),
G S 2 6 1(11,84), GS 12 (16,87) and GS 152 (17,91). Am plisize/2.5Kb m arker (M ) bands are labelled 
as equivalent sizes in repeats. Mols = molecules. Frequent small length changes can be observed 
with increasing allele size, although the 91 repeat o f GS152 seems more stable than the 87 repeat 
o f GS12.
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Figure 4.3 Large scale SP-PCR at the CTG18.1 locus on DNA isolated from sperm. Large 
scale SP-PCR at the CTG18.1 locus on high concentration DNA samples GS66 (11,37),
GS261 (11,84), GS12 (16,87) and GS152 (17,91). Am plisize/2.5Kb m arker (M) bands are labelled 
as equivalent sizes in repeats. Mols = molecules. Frequent large length changes can be observed from 
the 87 repeat o f sample GS12.
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Figure 4.4 Large scale SP-PCR at the ERDA1 locus on DNA isolated from sperm. Large scale 
SP-PCR at the ERDAI locus on single molecule and high concentration DNA from sperm sam ples 
GS94 (10,35), G S20 (10,59) and GS306 (10,81). A m plisize/2.5Kb marker (M) bands are labelled as 
equivalent sizes in repeats. Mols = molecules. An expansion can be seen in the high concentration DNA 
of sample G S20 from the 59 repeat allele.
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Figure 4.5 Fluorescent PCR on single molecule sperm DNA at the CTG18.1  locus. Second round 
PCR was carried out w ith primers SEF2-C-F/BR on single molecule PCR products from sperm , the 
products separated on a 4 .7 5 ^  polyacrylam ide gel and analysed with GeneScan 3.1 software. 
GS2500ROX standard is red, PCR products arc blue. Mols = molecules. Changes in repeats o f the upper 
allele are depicted above each lane. GS153 (11,38) shows mainly changes o f -1 to +1 repeats, although 
a 6 repeat expansion is evident in the final lane. GS166 (11,71) shows a higher degree o f instability with 
larger length changes of mainly -2 to +2 repeats and a -10 repeat contraction can be detected.
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Figure 4.6 Fluorescent FCR on single molecule sperm DNA at the ERDA1  locus. Second round 
PCR was carried out with primers ERD A-A-F/DR on single m olecule PCR products from sperm, the 
products separated on a 4.75% polyacrylam ide gel and analysed with GencScan 3.1 software. 
GS25(X)ROX standard is red, PCR products are blue. Mols -  molecules. Changes in repeats of the 
upper alieie are depicted above each iane. GS174 ( 16,29)is very stable and shows no mutations.
GS 110 (10,74) shows a higher degree o f instability with length changes o f mainly -2 to +2 repeats.
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Figure 4.7. GeneScan profiles of second round fluorescent PCR on single molecule PCR products.
Depicted are GeneScan profiles o f single m olecule PCR products from sperm samples GS153 (11,38) 
and GS 166 (11,71) at the CTG18.1 locus and G S174 (16,29) and G S110 (10,74) at the ERDA1 locus. 
Stutter bands can be seen as sm aller peaks preceding the main peak and in larger alleles, as a ‘hedgehog’. 
CTG18.1 alleles have a larger spread of stutter bands than ERDA1 alleles with increasing repeat length. 
Filled peaks depict the upper allele for each sample and the respective repeat sizes arc labelled.
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Figure 4.8 Allele frequency distributions from single molecule anlaysis at the CTG18.1 locus.
Displayed are the allele frequency distributions from single molecule PCR analysis of sperm from three 
heterozygous individuals GS66 (11,37), GS130 (31,40) and GS12 (16,87) at the CTG18.1 locus. There is 
increasing mutation rate with increasing allele length resulting in a larger spread of alleles as the repeat 
increases in length. Between the 30-40 repeat range there is a 20% decrease of the progenitor allele and 
in sample GS12 the frequency of the progenitor can be seen to be only slightly higher than the mutant 
alleles surrounding it.
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Chapter 5
Other factors influencing repeat stability
5.1 Somatic mosaicism at the CTG18.1 locus
5.1.1 Introduction
One of the simplest tissues to obtain from patients is blood and hence SP-PCR has been used 
to observe repeat behaviour in tissues other than the germline (i.e. in the soma). In the case of 
myotonic dystrophy, extensive SP-PCR analysis has been carried out on blood and muscle, 
either because of their ease of extraction or their association with the disease phenotype. 
Muscle is particularly prone to expansion, but blood is more stable and often used for 
diagnostic purposes. However, it has been noted that over a period of time, the repeat 
distribution in the blood can also “shift” to a larger average size with a greater spread of 
alleles (Martorell et a l , 1998) and hence the age of the individual and the size of the repeat can 
make it increasingly difficult to predict the progenitor. This has consequences for diagnostic 
purposes where it may seem there are apparent contractions in transmission of the repeat, and 
correlations between genotyping and age of onset which could suggest that symptoms could 
develop earlier than would be the case.
It is known that the DM-1 repeat shows contrasting behaviour in cultured lymphoblastoid cell 
lines to the somatic tissue it is derived from (Ashizawa et a l, 1996). CEPH DNA is extracted 
from transformed lymphoblastoid cell lines established from the lymphoblasts of individuals 
from large families. Cell lines established with clones from DM-1 patients demonstrated that 
the repeat does mutate, but not at a high rate (Ashizawa et a l, 1996). SP-PCR showed that 
these mutations are biased toward contractions, from a progenitor of 230 repeats at a rate of 
40% for small length changes and 1% for large length changes, increasing to 75 and 20% 
respectively with further doublings. A progenitor of 1100 repeats had a mutation rate of 70% 
for small length changes and 10% for large length changes, also biased toward contractions. 
The first publication of the CTG18.1 locus analysed BPAD families for expanded alleles as 
well as CEPH DNA to ascertain whether instability at this locus could contribute to the 
phenotype (Breschel et a l, 1997). Expanded alleles were detected in CEPH and BPAD DNA 
as well as unaffected individuals in disease families. Therefore, CTG18.1 was discounted as a 
BPAD mutation. It was reported however, that large CTG18.1 expanded alleles were detected
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in two CEPH families, 1344 and 1420. Therefore in order to observe expanded repeat 
behaviour in DNA derived from somatic tissues, CEPH DNA from families 1332, 1344 and 
1420 and blood DNA from DM-1 patients were analysed by SP-PCR at the CTG18.1 locus.
5.1.2 Results
In order to observe somatic behaviour at the CTG18.1 locus and compare to the male 
germline, blood DNA available from 50 DM-1 patients were typed (Appendix 1) and five 
individuals were identified to have CTG18.1 expansions. The range of alleles detected was 
11-89 repeats. All five samples underwent preliminary SP-PCR analysis at CTG18.1 and 
three are displayed in Figure 5.1. Samples 101-4004 and 101-3056 are relatively stable 
having upper alleles of 51 and 69 repeats respectively, with a mutation frequency of 
approximately 16-18%. Sample 152-3021 has a larger allele of 89 repeats and demonstrates 
an increased mutation frequency of 37% but with expansions, rather than contractions as 
observed in the male germline. The distribution of alleles in the blood is similar to that seen at 
the DM-1 locus in patients, in that there is a defined lower boundary and a bias toward 
expansions, though not to the same scale (Monckton et a l , 1995, Martorell et a l, 1998).
The CEPH DNA of the Fathers (F-01) and Mothers (M-02) of families 1332, 1334, 
1344,1420 and 1424 were typed by PCR at the CTG18.1 locus. Alleles ranged from 11-330 
repeats (Appendix 1). Alleles up to 118 repeats were detectable by fluorescent PCR and the 
expanded allele of 330 repeats was estimated by PCR Southern blot. Preliminary SP-PCR at 
the CTG18.1 locus on samples M-02 1332 (11, 52) and M-02 1344 (17, 118) and large scale 
SP-PCR on sample F-01 1420 (15, 330) are displayed in Figure 5.2. The 52 repeat allele is 
relatively stable, demonstrating approximately 2% large length changes, the 118 repeat allele is 
demonstrating 8.7% large length changes, and the 330 repeat allele is mutating at a frequency 
of 11%, sometimes into the normal range. This contrasts with the observed increased 
instability in the blood DNA from DM-1 patients for similarly sized alleles and there is an 
upper boundary for mutations as opposed to a lower boundary.
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5.1.3 Discussion
A limited number of blood DNA samples with CTG18.1 expansions were available to analyse 
tissue-specific differences, but a behaviour change can be detected. Alleles at the CTG18.1 
locus have a tendency toward contraction in the male germline but to expand in the blood. 
SP-PCR data on triplet repeat sequences indicates trinucleotides are more stable in blood than 
the germline, but there is a lack of published data for an equivalent repeat range as that 
examined in this section. For example, extensive SP-PCR has been carried out on blood 
DNA from DM-1 patients (Monckton et a l, 1995, Martorell et a l, 1998), demonstrating that 
although the repeats are more stable in this tissue than others such as sperm and muscle, there 
are frequent mutations that are biased toward expansions. The published data available for 
DM-1 alleles of the 50-100 repeat range suggests there are mutations ranging from 
approximately 30-100 repeats (Monckton et a l, 1995). Unpublished SP-PCR data does 
suggest that alleles of 60-90 repeats have increasing mutation rates with the occasional 
expansion up to 210 repeats for larger alleles and one sample with a 118 repeat allele had a 
range of 98-275 repeats (Hogg and Monckton, unpublished). Therefore the rate of mutation 
at the CTG18.1 locus in sample 152-3021 {21, 89) is subtle compared to the behaviour 
observed at the DM-1 locus with similarly sized alleles. The range of ages for the blood 
samples is 20-64 years of age and the youngest individual sampled was 152-3021, indicating 
that if there is an age effect, it is subtle compared to DM-1. It would be interesting to see if 
there is a time effect at the CTG18.1 locus as in the case of DM-1 and 152-3021 would be a 
good candidate for that study, due to the size of the allele and the age of the individual. This 
may also assist in models of DM-1 repeat behaviour where the alleles are so unstable that it is 
difficult to define a simple model.
CEPH DNA is available in order to provide large numbers of transmissions within families in 
which to study human genetics. In the case of the CTG18.1 repeat, CEPH families were 
screened in order to establish that normal individuals do not possess expanded alleles 
(Breschel et a l, 1997). However, various expanded alleles were discovered in healthy 
individuals with no history of serious illness. It was not stated how large these alleles were 
and so these individuals were typed at the CTG18.1 locus. Sample F-01 1420 (15, 330) had 
the largest allele detected by PCR which was evident only on a PCR Southern blot and could 
not be detected using fluorescent primers. Therefore as this allele was the largest available at 
the CTG18.1 locus, it was subjected to SP-PCR. The data seems to indicate that large alleles 
are relatively stable in cultured lymphoblastoid cell lines and show contrasting behaviour to 
the tissue they originate from. From the DM-1 patient blood data, it is known that the 
CTG18.1 repeat is likely to expand rather than contract with increasing allele length in blood. 
It is also known that the DM-1 repeat is biased toward expansions in the blood as
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demonstrated by SP-PCR (Monckton et al, 1995, Martorell et a l, 1998). However it is also 
known that the DM-1 repeat also shows contrasting behaviour in cultured lymphoblastoid cell 
lines (Ashizawa et a l, 1996). Cell lines established from a clone from DM-1 patients 
demonstrated that the repeat does mutate, but not at a high rate, and SP-PCR showed that 
these mutations are biased toward contractions from progenitors of 230 and 1100 repeats. 
Sample F-01 1420 also showed that this large allele of 330 repeats at the CTG18.1 locus is 
contracting and no expansions were detected, although only a total of 758 molecules were 
analysed. DM-1 alleles do expand occasionally in these cell lines, whereas the expanded 
CTG18.1 allele was seen to be more stable in regard to expansions. Therefore it seems that 
large, expanded alleles will generally contract in cultured lymphoblastoid cell lines but the 
flanking sequence of the repeat determines the subtle mutations that occur and can only be 
detected by SP-PCR. The DM-1 locus is more unstable than the CTG18.1 locus and so still 
demonstrates some expansions from a 230 repeat allele. The CTG18.1 locus is not as prone 
to gross expansions from equivalently sized alleles and so this 330 repeat is not expanding 
though it might be expected to, given its length.
5.2 Instability at the CTG18.1 locus in MMR deficient tissues
2.5.1 Introduction
Since the discovery of the DNA mismatch repair gene mutations giving rise to HNPCC, much 
work has focused on microsatellite instability at many loci distributed over the entire genome. 
Various approaches have been taken in order to select which markers may be more 
informative or sensitive to the RER+ phenotype, either based on previous MEN-i- observations, 
marker location in respect to the MMR genes, or the availability of markers within the 
research group. Most observations have been with dinucleotide (CA) markers due to their 
availability in the genome. Microsatellite instability has also been investigated in various types 
of ovarian cancer, although the overall incidence is low compared to that seen in HNPCC 
tumour DNA. MIN+ is usually associated with the less severe forms and early FIGO stages 
of ovarian cancer (Park et a l, 1995, Pieretti et al, 1995, Tangir et a l, 1996), although it is not 
widespread in the genome, whereas in HNPCC MIN+ is much more common at a wide range 
of markers (Aaltonen et a l, 1993, Ionov et al, 1993, Lindblom et a l, 1993, Thibodeau et a l, 
1993, Aaltonen et a l, 1994, Pedroni et al, 1999). Cases of ovarian cancer where the tumour 
has demonstrated instability at more than one marker are therefore thought to have derived 
from individuals within HNPCC families (Arzimanoglou et a l, 1996, Phillips et a l, 1996) and
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MMR mutations have been detected in some of these tumours. Of great importance is to 
characterise the underlying germline MMR mutation as it has been noted that hMLHl 
mutations seem to confer a higher rate of microsatellite instability than hMSH.2 mutations 
(Lamberti et a l , 1999, Wu et a l, 1999). Therefore we sought to test if microsatellite 
instability could be detected at the CTG18.1 locus in ovarian tumours and whether this 
instability could be replicated in HNPCC tumours with a known MMR deficiency.
2.5.2 Results
DNA was available from an ovarian carcinoma cell line, A2780 and cisplatin resistant 
derivatives of this cell line, known as MCP1-9 (Anthoney et a l, 1996). A2780 is known to be 
proficient in hMLHl, hMSH2, hPMS2 and hMSH6, whereas the MCP derivatives are 
deficient in hMLHl and hPMS2 (Brown et a l, 1997). MCP1 and 8 are partially methylated at 
four Hpall sites in the hMLHl promoter, whereas MCP3, 5 and 7 are fully methylated 
(Strathdee et a l, 1999). Cell line LoVo is deficient in both hMLHl and hMSH2 and AN3CA 
is an endometrial cell line deficient in hMLHl (Umar et a l, 1994). In order to test if any 
deficiencies in the MMR genes could alter the stability of trinucleotide repeats, these cell lines 
were typed at the CTG18.1, ERDAI and DM-1 loci. Alleles ranged from 10-28,9-20 and 5- 
13 repeats respectively (Appendix 1). The derived cell lines MCP 1-9 were stable at the DM-1 
and ERDAI loci, but the upper CTG18.1 allele of 27 repeats mutated by -1 and +1 repeats at 
the CTG18.1 locus respective to the parental cell line A2780. This suggests that the alleles at 
the DM-1 and ERDAI loci are too small to be affected by defects in mismatch repair, but that 
the larger allele at the CTG18.1 locus is large enough to mutate due to errors in replication 
and hence would avoid correction.
Blood and ovarian tumour DNA was also available from 15 individuals who were typed at 
CTG18.1, ERDAI and DM-1. Alleles ranged from 11-64, 10-68 and 5-26 repeats 
respectively (Appendix 1). Given the sensitivity already noted in the cell lines at the CTG18.1 
locus, blood sample LC (11, 64) underwent preliminary SP-PCR at the CTG18.1 locus. No 
increased instability was observed from the blood DNA samples analysed in Section 5.1. SP- 
PCR on the tumour DNA from this individual proved difficult and no definite conclusions 
could be drawn on instability due to PCR inhibitors that may be a result of the paraffin fixing 
process.
DNA extracted from four ovarian tumours were typed and alleles ranged from 11-106, 10-60 
and 5-13 repeats at CTG18.1, ERDAI and DM-1 respectively (Appendix 1). Sample OT481 
(17, 106) underwent preliminary SP-PCR at the CTG18.1 locus and demonstrated high levels
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of instability of the upper allele, heavily biased toward expansions (Figure 5.3) although the 
majority of alleles are close in size to the progenitor, which is demonstrated by fluorescent 
PCR (Figure 5.9). There is a definite lower boundary and though alleles have increased to 
over 600 repeats in length, the majority of upper alleles are between 106 and 170 repeats.
There is no additional information such as age of individual, stage of tumour or germline 
MMR mutations which would help to assess if the behaviour observed is a response to 
defects in mismatch repair or other factors. In order to test if this microsatellite instability is 
widespread, other trinucleotide repeat loci were investigated. Normal alleles at loci DM-1 (5, 
13), ERDAI (21, 60), SBMA (17,25) and SCA1 (28) were stable in this tumour sample 
(Figure 5.4). Therefore, this gross instability appears to be specific to the expanded allele at 
the CTG18.1 locus.
The mismatch repair status of OT481 is unknown, so in order to discover if this gross 
microsatellite instability could be replicated in tumours known to have defective mismatch 
repair status, loci CTG18.1 and ERDAI were investigated to see if expanded alleles would 
behave differently in HNPCC tissue, either tumour or non-tumour compared to the somatic 
behaviour already observed in blood (Section 5.1). Blood DNA was available from a total of 
83 HNPCC individuals from 53 families and 162 chromosomes were typed at both CTG18.1 
and ERDAI. The ranges of alleles were 11-93 and 7-86 repeats respectively (Appendix 1). In 
order to screen the blood DNA samples for expanded alleles demonstrating instability without 
using SP-PCR, typing PCR products at the CTG18.1 locus were electrophoresed through a 
1.75% agarose gel, subjected to a Southern blot and radioactively hybridised. Figure 5.5 
displays the Southern blot of the PCR typing at the CTG18.1 locus on blood DNA from 
HNPCC individuals. Two samples, EE and her mother FT, have both inherited the same 
germline 2bp deletion in exon 19 of hMLHl and an expanded CTG18.1 allele of 93 repeats. 
These two samples have produced a smear on the Southern blot in addition to the upper allele 
that can be detected at approximately 100 repeats. This indicates a varied population of repeat 
sizes in these samples and so the more sensitive technique of SP-PCR was applied at this 
locus in these samples and a third, BeMa, which also has an expanded allele of 81 repeats (not 
shown).
To establish the mutation rate of the 93 repeat allele in normal tissue from HNPCC samples 
EE and FT and the 81 repeat allele in BeMa, blood DNA underwent preliminary SP-PCR at 
the CTG18.1 locus (Figure 5.6). The 93 repeat alleles of FT and EE clearly show dramatic, 
expansion biased instability which can also be detected by fluorescent PCR though not to the 
same extent (Figure 5.9). The upper allele of FT has expanded to greater than 770 repeats at a 
high frequency with no definite lower boundary. The upper allele of daughter EE is also 
expanding to greater than 770 repeats but the majority of alleles are between 93 and
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approximately 270 repeats in size, with a definite lower boundary at the progenitor allele of 93 
repeats. As both individuals inherited the same MMR mutation it is assumed that this 
difference is due to the age effect. FT was 83 years old at time of sampling and her daughter 
EE was 54. The 81 repeat allele of BeMa however is much more stable both in SP-PCR 
(Figure 5.6) and fluorescent PCR (Figure 5.9). Unfortunately there is no information 
available about the age or inherited MMR mutation for BeMa, although the individual is 
female, as in the cases of FT and EE. BeMa has a similarly sized expansion allele at 
CTG18.1 but it is much more stable than the upper alleles of FT and EE. However, this allele 
is still more unstable than similarly sized alleles in the blood of DM-1 patients (Section 5.1).
The extreme behaviour of the expanded CTG18.1 allele in samples FT and EE compared to 
the blood DNA samples analysed from DM-1 patients (Section 5.1) and HNPCC sample 
BeMa suggests that it is a response to a specific MMR mutation. The blood DNA is 
heterozygous for the 2bp deletion and so the tumour would be predicted to have accumulated 
another mutation in hMLHl in the colon tissue. It was therefore expected that the expanded 
CTG18.1 allele would be relatively stable in blood in order to compare against any increased 
instability observed in tumour DNA. However, the preliminary SP-PCR suggests that some 
additional mechanism may be operating to contribute to this gross instability. To determine if 
other trinucleotide repeats were also being affected by this additional mechanism, the blood 
DNA of FT and EE underwent SP-PCR at the DM-1, ERDAI, SBMA and SCA1 loci (Figures 
5.7 and 5.8). Both samples had normal alleles at all four loci which were stable.
Tumour DNA was available for EE and so it also underwent preliminary SP-PCR to assess 
the behaviour of the CTG18.1 locus in response to total deficiency in hMLHl (Figure 5.10). 
Only the lower allele could be detected in the tumour DNA and this seemed unstable. There 
was very little DNA in the sample as there were only intermittent positive reactions for the 
lower allele, but using undigested, and hence more concentrated DNA instead of Hindlll 
digested DNA did not increase the number of positive reactions. This suggests that the DNA 
could have been damaged when the tumour was set in the paraffin block and so PCR would 
not work as well. The other possibility is that the repeat has expanded outside the limits of 
detection by PCR. In order to visualise PCR products from the upper allele that could not be 
resolved on the SP-PCR blot, the 8 reactions for either digested or undigested underwent a 
second round fluorescent PCR and the products electrophoresed through a 4.75% 
polyacrylamide gel and analysed with GeneScan 3.1 software (Figure 5.11). The upper allele 
was not detected and so it was concluded that there was not enough DNA from the tumour to 
analyse the behaviour of the expanded CTG18.1 allele in response to total deficiency of 
hMLHl.
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Expanded ERDAI alleles were also available to analyse if this locus could demonstrate the 
same type of instability seen at CTG18.1. Preliminary SP-PCR was carried out at the ERDAI 
locus (Section 2.3) on HNPCC blood samples JC (21, 62) and NS (10, 75) (Figure 5.12). JC 
has inherited a G to A transition in exon 19 of hMLHl creating a premature STOP codon and 
NS has inherited a lbp deletion in exon 6 of hMSHl. Both alleles of each sample are very 
stable at the ERDAI locus in blood. From the male germline data in Section 4 it is known that 
the ERDAI locus is much more stable than CTG18.1. Therefore it is not surprising that it is 
also very stable in blood and unlikely to produce mutations that would evade correction by the 
mismatch repair machinery. Therefore it would still appear stable.
Colon tumour DNA available from HNPCC individual BaF, who has inherited a 2bp insertion 
in exon 1 of hMLHl and an ERDAI expansion of 60 repeats, demonstrates stability at the 
ERDAI locus at both the normal and expanded alleles (Figure 5.10). There is an extra band 
evident in the sample, but this product is often detected in ERDAI SP-PCR, varying in size 
between the two alleles, although it is not contamination and thought to be an artefact. The 
brother of BaF, BF also inherited the same HNPCC germline mutation and expanded ERDAI 
allele and also demonstrated stability in the blood (data not shown). Tumour tissue from BF 
was fixed in a paraffin block, the DNA extracted and subjected to SP-PCR at the ERDAI 
locus. Although both alleles could be detected with typing primers ERDA-C/DR on an 
agarose gel, neither allele was observed with SP-PCR primers ERDA-A/BR. In order to 
visualise the PCR products that could not be resolved on the SP-PCR blot, the 8 reactions of 
the most concentrated input DNA underwent a second round fluorescent PCR and the 
products electrophoresed through a 4.75% polyacrylamide gel and analysed with GeneScan
3.1 software (Figure 5.11). Both alleles were detected, but artefacts can also be seen. 
However, it does seem that this tumour DNA is also stable at this locus for both the expanded 
and normal alleles, as in tumour sample BaF.
2.5.3 Discussion
The cell line DNA all possessed small alleles at the DM-1, CTG18.1 and ERDAI loci and 
given the observations that only expanded alleles seem to demonstrate instability, SP-PCR 
was not pursued in these samples. However, it was noted that the hMLHl deficient cell lines 
MCP 1-9 derived from a MMR proficient cell line A2780, are unstable for the 27 repeat at the 
CTG18.1 locus. Of the seven cell lines known to be MLH1 deficient, 4/7 gained a repeat, 1/7 
lost a repeat and 2/7 remained stable. Though information on the status of hMLHl, hMSH2, 
hPMS2 and hMSH6 is available, it does not directly correlate with the gain or loss of a repeat.
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It cannot be ignored however that the 27 repeat is demonstrating a higher frequency of 
mutations than would be expected if the cell lines were hMLHl proficient.
Given the limited number of ovarian tumour DNA samples available for SP-PCR analysis, it 
was fortunate to discover a sample with an expanded allele at the CTG18.1 locus, as the 
frequency of expanded alleles is 3%. The expanded allele of 106 repeats in sample OT481 is 
demonstrating a higher mutation rate compared to the blood DNA from DM-1 patients in 
Section 5.1. There is no data available regarding the MMR status, age of individual or type of 
ovarian tumour which could give some clues as to why this expanded allele is demonstrating 
gross instability at the CTG18.1 locus. It could be this individual has inherited a hMLHl 
mutation which is most likely to contribute to microsatellite instability, that she could have an 
early age of onset given the definite lower boundary of the expanded allele, or that the tumour 
itself could have been in the early FIGO stages as they have the greatest frequency of 
microsatellite instability. SP-PCR at other trinucleotide loci DM-1, ERDAI, SBMA and SCA1 
confirmed that the observed microsatellite instability was specific to CTG18.1, although all 
loci had normal alleles which have reduced mutation rates and hence it would be improbable 
that similar behaviour would be evident.
Microsatellite instability was detected in HNPCC tumour samples before the underlying 
MMR mutations were identified (Aaltonen et al, 1993). It has been postulated that 75-100% 
of HNPCC tumours demonstrate microsatellite instability whereby the size of alleles differs 
between normal and cancerous tissue from the same individual (Aaltonen et a l, 1993), 
(Aaltonen et a l, 1994, Lindblom et a l, 1993) compared to sporadic colon tumours that show a 
low frequency of the MIN+ genotype (Pedroni et a l, 1999). Observations seem to suggest 
that mutations in the hMLHl gene confer a higher rate of microsatellite instability than other 
MMR genes (Lamberti et a l, 1999, Wu et a l, 1999), and 90% of sporadic tumours with high 
MIN+ status have loss of expression or hypermethylation of hMLHl (Cunningham et a l, 
1998, Thibodeau et a l, 1998). In order to observe microsatellite instability at the CTG18.1 
and ERDAI loci, HNPCC blood samples were screened and expanded alleles were identified. 
Preliminary SP-PCR uncovered extreme instability of a 93 repeat allele at the CTG18.1 locus 
in two members of a HNPCC family with a 2bp deletion in exon 19 of the hMLHl gene.
This instability in the normal tissue in response to a heterozygous MMR mutation has been 
detected before at di and mononucleotide markers in the lymphoblasts and colon of two 
siblings who have inherited the same hPMS2 mutation (Parsons et a l, 1995). There had been 
no subsequent somatic mutation of the normal hPMS2 gene or of other MMR genes, so it was 
suggested that this mutation was creating a dominant negative effect on the protein. In this 
case, the final six amino acids of hMLHl preceding the STOP codon have been altered to a 
Serine and Leucine before a premature STOP. These final six amino acids are 100%
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conserved in the human, rat, yeast and Drosophila homologues and only one amino acid 
change is observed in the Arabidopsis thaliana MHL1 gene (Figure 5.13) (Prolla et al., 1994, 
Kolodner et al., 1995, McKee 1998, Geeta Vani et al., 1999, Jean et al., 1999). The fact that 
the extreme carboxy terminus of this gene is so highly conserved suggests these final amino 
acids are essential for the function or location of MLH1, although it is not known whether this 
region is part of a domain that could be responsible for protein interactions. The gross 
instability observed in blood samples FT and EE at the CTG18.1 locus therefore suggest a 
possible dominant negative mutation in the hMLHl gene. It could be that the change in the 
amino acid sequence of the extreme carboxy terminus would allow the mutated protein to 
interact with the normal hMLHl protein or proteins from the MMR pathway and hence 
reduce overall function. Alternatively, the mutated hMLHl gene could not be directly 
responsible for the observation at the CTG18.1 locus and inherited haplotypes in the flanking 
sequence or mutations in other genes could be major contributors. Ideally, we would need to 
analyse other members of this family to assess the expanded CTG18.1 repeat in individuals 
who do not possess the hMLHl mutation. Only by analysing more blood DNA samples 
from normal individuals with an expanded CTG18.1 repeat can this gross instability be 
attributed to defects in mismatch repair.
r M L H l LA NLPDLC K VFER C
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Figure 5.13 Comparison of hMLHl C-terminus amino acid sequence. Alignment of the last 
14 amino acids of the MLH1 gene from rat (Geeta Vani et al., 1999), arabidopsis thaliana 
(Jean et al., 1999), human (Kolodner et al., 1995), Drospohila (McKee 1998) and yeast 
(Prolla et al., 1994). The last four amino acids are 100% conserved between all species, 
suggesting they are extremely important.
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Both samples are displaying expanding repeat behaviour in response to increasing age of 
individual as seen in other triplet repeats such as DM-1 (Monckton et a l, 1995, Martorell et 
al., 1998). Sample FT has a less definite lower boundary than EE and a greater frequency of 
very large alleles. This suggests therefore that age dependent expansion is a feature of large 
CTG alleles independent of the flanking sequence. The extreme microsatellite instability 
observed for the ovarian tumour OT481 and HNPCC tissues has been noted for the DM-1 
CTG repeat in tumourous tissue from DM-1 patients. A Japanese woman was typed to have 
approximately 1,500 repeats in the blood, but over 5,000 repeats in the ovarian cancer 
(Kinoshita et a l, 1997) and three DM-1 patients with various cancers had increases of up to 
3,000 repeats in the tumour compared to DNA from the non-tumour tissue (Jinnai et al.,
1999).
Further investigations into possible instability at other trinucleotide repeat loci in blood DNA 
samples FT and EE revealed that normal alleles were stable and the instability observed is 
specific to the expanded allele at the CTG18.1 locus. Therefore the small alleles at the 
CTG 18.1, DM-1, ERDA1, SBMA and SCA1 loci are easily replicated within the blood DNA 
with no errors incurred. SP-PCR at the CTG18.1 locus in the tumour DNA of EE suggests 
the second “hit” in the MMR machinery that subsequently triggered tumour formation is 
also failing to correct errors introduced into the small allele. The large allele of 93 repeats 
could not be detected which suggests there was low quality DNA from the tumour or that the 
upper allele has expanded outside the limits of PCR detection. If more concentrated DNA 
was available from this tumour, then the DM-1, ERDA1, SBMA and SCA1 loci could be 
analysed for any differences to the blood, or to answer the question of the size of the upper 
allele, possibly by restriction digestion and a Southern blot.
The lack of information regarding the germline mutation inherited by individual BeMa means 
it is not possible to comment on the relative stability of the expanded allele compared to FT 
and EE, although the blood results would provide a basis for comparisons with tumour DNA. 
Due to the prevalence of different MMR mutations giving rise to HNPCC, it is assumed that 
HNPCC blood sample BeMa does not have the same MMR mutation. If BeMa does have the 
same mutation however, it is possible that this individual is young and there could be an age 
effect which would explain the difference to FT and EE.
The ERDA1 locus was also investigated to observe any microsatellite instability in HNPCC 
tissue. Expanded alleles were detected and the blood and tumour DNA from two siblings, 
BaF (10, 60) and BF (10, 60) who inherited a 2bp insertion in exon 1 of hMLHl, were 
subjected to SP-PCR. Blood DNA was stable for each allele at this locus in both individuals 
and investigation of tumour DNA also found the locus is stable. The ERDA1 locus also
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proved very stable in blood samples JC (21, 62) and NS (10, 75). JC inherited a G to A 
transition in exon 19 of hMLHl creating a premature STOP codon and NS inherited a lbp 
deletion in exon 6 of hMSH2. The mutation JC inherited is further upstream in hMLHl than 
the premature STOP codon inherited by individuals FT and EE, suggesting that either the 
ERDA1 locus does not have a sufficient level of instability to be affected by defective hMLHl 
or that the change of amino acids is more important than the STOP codon in altering hMLHl 
function. In future experiments, detection of ERDA1 alleles in fixed tissue DNA could be 
improved by carrying out a first round SP-PCR followed by a second round fluorescent PCR. 
In tumour sample BF, ERDA1 alleles could not be detected from first round SP-PCR, but 
were clearly observed after second round fluorescent PCR and GeneScan analysis. This 
confirmed that this sample was also stable.
Many ovarian tumour and blood samples from the same patients need to be screened in order 
to verify the results depicted in this section. Testing for MMR mutations and other features 
of ovarian cancer genetics such as LOH and mutations in genes such as KRAS, BRCA-1 and 
p53 and classification of the FIGO stages and type of tumour would help to define the 
different mechanisms of mutation occurring. There also seems to be no continuity between 
sampling and analysis of markers in ovarian cancer or HNPCC, and although there are 
indications that certain types of tumour are more likely to be MIN+ than others, the crude way 
of determining microsatellite instability with larger quantities of DNA may not detect the type 
of instability seen in samples OT481, FT and EE. Dinucleotide repeats also seem to be stable 
which is reflected in the range of alleles at these markers. Therefore they are much less likely 
to mutate and may not be ideal candidates for observing microsatellite instability.
5.3 Repeat behaviour at the CTG18.1 locus in response to Radiotherapy treatment
5.3.1 Introduction
Analysis of samples in the previous sections has primarily been concerned with the natural 
behaviour at the CTG18.1 or ERDA1 loci in the male germline, and how the alleles at the 
CTG 18.1 locus exhibit different behaviour in somatic tissue and in response to deficient 
mismatch repair. These differences are due to the tissue or inherited genomic deficiencies in 
the individual. However, it has been suggested that influences such as chemical or ionising 
radiation can also change the status of the human genome. One example of chemical radiation 
affecting DNA is the fallout from the Chernobyl disaster. There has been a general increase 
in the incidence of cancer in families from areas such as Belarus and though elevated mutation 
rates have been observed for minisatellites in the germline of these sufferers (Dubrova et al., 
1997), there has been no significant microsatellite instability detected in the tumours 
(Nikiforov et al., 1998). With regard to ionising radiation, there was no significant difference 
in the mutation rate of a minisatellite, MS205 in sperm before and after radiotherapy, 
detectable by SP-PCR (Armour et al., 1999). Due to the sensitivity of the CTG 18.1 locus in 
response to defective MMR, this locus was tested to see if the stability of a microsatellite 
could be affected by exposure to radiation.
5.3.2 Results
Sperm DNA samples were obtained from several patients before and after radiotherapy 
treatment for testicular cancer. Typing PCRs were carried out at the DM-1, CTG 18.1 and 
ERDA1 loci with ranges of 5-34, 11-31 and 10-65 repeats respectively (Appendix 1). Sperm 
DNA samples taken before and 65 days following treatment of individual XRT1970 (5, 34) 
(11,31) (22, 22) underwent single molecule SP-PCR at both the CTG 18.1 and DM-1 loci, 
followed by a second round fluorescent PCR and the products electrophoresed through a 
4.75% polyacrylamide gel and analysed by GeneScan 3.1 software. The preliminary SP-PCR 
at each locus does not indicate any gross differences between the samples (Figure 5.14). The 
frequencies of the larger allele at each locus following second round fluorescent PCR analysis 
are displayed in Table 5.1 and Figure 5.15. The CTG18.1 locus was stable before and after 
treatment with a slight increase in the number of progenitor alleles after treatment, from 94.5 
to 95.3% and a tighter distribution of mutations from 25-33 repeats to 30-33 repeats. The 
DM-1 locus is known to be more unstable and though the difference in progenitor alleles at 
these two loci is only 3 repeats, there is approximately a 40% difference in progenitor
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frequency. The progenitor allele of 34 repeats increases from 41.7 to 47.8% at the DM-1 
locus after treatment and the distribution of alleles changes from 27-42 repeats to 28-39 
repeats. These slight differences between the samples before and after treatment are most 
likely a result of the time difference between collection of samples or limits of the number of 
molecules analysed for each locus.
5.3.3 Discussion
Though only one sperm sample was analysed in detail at two trinucleotide repeat loci, there 
does not seem to be an effect of radiation on their behaviour. It would be assumed that the 
radiation would induce a mutation in genes that would either leave mutations in these 
microsatellites unchecked or introduce a greater frequency of errors into the length of the 
repeat. In fact the trinucleotides seem to be stable and the slight differences between the two 
samples at either locus is due to the small number of molecules analysed or just stochastic 
variation. Based on single molecule observations at the DM-1 locus in the male germline 
(Appendix 2), the DM-1 34 repeat allele has a mutation rate and average length change 
expected for a 35-36 repeat allele. This mutation rate and average length change are slightly 
elevated from that displayed in the DM-1 single molecule data but likely to be a result of small 
numbers of samples analysed in that range. The behaviour of the 31 repeat allele at the 
CTG 18.1 locus is much more subtle, which is to be expected given the smaller allele length 
and the stability of this locus compared to DM-1. A Chi-squared test on the positive reactions 
found no evidence for meiotic drive between the upper and lower alleles at either locus.
The limited data documented here in combination with studies on individuals bom to parents 
who had paediatric cancer found no increased risk of genetic disease (Byme et al., 1998). 
Therefore this suggests there are no adverse effects of radiotherapy on the male germline. 
Further studies at microsatellite and minisatellite loci would help to advise male patients of the 
risks of having children after radiotherapy treatment.
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Figure 5.1 Preliminary SP-PCR on blood DNA at the CTG18.1 locus. Prelim inary SP-PCR 
at the CTG 18.1 locus was carried out on blood DNA extracted from DM-1 patients. Displayed 
are sam ples 101-4004(11,51), 101-3056 (15,69) and 152-3021 (27,89) with respective expanded 
D M - 1 alleles of 800, 500 and 500 repeats. Am plisize/2.5Kb marker bands are labelled as equivalent 
sizes in repeats. Mols = molecules. There is an increasing mutation rate with increasing allele size 
and a defined lower boundary below which mutations do not occur. M utations are biased toward 
expansions but at a lower frequency than the DM-1 locus.
91
6 mols / reaction 0.6 mol / reaction
2 mols / reaction 0.2 mol / reaction
m m
F-01 1420
M
* *
16 mols / reaction M
-437
-271
-171
-104
-71
-37
-4
Figure 5.2 SP-PCR at the CTG18.1 locus on lymphoblastoid cell line (CEPH) DNA. Prelim inary 
SP-PCR at the CTG 18.1 locus on CEPH DNA samples M-02 1332 (11,52), CEPH M -02 1344 (17,118) 
and CEPH F -011420 (15,330). Am plisize/2.5Kb marker bands (M) are labelled as equivalent sizes in 
repeats. Mols = m olecules. M-02 1332 has a mutation rate of 2%, M-02 1344 has a mutation rate o f 8.7% 
and F-01 1420 has a m utation rate o f 11%. Therefore there is an increasing m utation rate w ith increasing 
repeat length, biased toward contractions.
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Figure 5.3 Preliminary SP-PCR at the CTG18.1 locus on ovarian tumour DNA. Ovarian tumour 
sam ples OT437 (16,16), OT450 (11,11) and OT481 (17,106) underwent prelim inary SP-PCR at the 
CTG 18.1 locus. Am plisize/2.5Kb marker (M) bands are labelled as equivalent sizes in repeats. Mols 
= molecules. Tum our OT481 is dem onstrating instability o f the 106 repeat allele, biased toward 
expansions of up to 500 repeats.
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Figure 5.4 Preliminary SP-PCR at multiple trinucleotide repeat loci on ovarian tumour DNA sample 
OT481. Preliminary SP-PCR was carried out on ovarian tumour DNA sample O T481 at the DM-1, ERDA 1, 
SBMA and SCA1 loci. Am plisize/2.5Kb marker (M) bands are labelled as equivalent sizes in repeats. 
M ols = molecules. Sizes of alleles at DM-1 and ERDAl were determ ined by fluorescent PCR with 
GeneScan analysis and at SBMA and SCA1 by Kodak ID Image analysis software. All loci are stable, 
though one expansion can be seen from the 60 repeat allele at the ERDA 1 locus.
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Figure 5.5 PCR Southern blot of typing PCR at the CTG18.1  locus. PCR allele typing at the 
CTG 18.1 locus was carried out on blood DNA of HNPCC individuals and the products 
Southern blotted. 1Kb marker (M) bands are labelled as equivalent sizes in repeats.
Sam ples EE (16, 93) and FT (11, 93) demonstrate bands at approxim ately 100 repeats, 
but also a sm ear that is indicative of gross expansion. Sample RW (17, 54) also has a slight 
sm ear though SP-PCR showed this sample was stable.
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Figure 5.6 Preliminary SP-PCR at the CTG18.1 locus on blood DNA from HNPCC individuals.
Prelim inary SP-PCR at the CTG 18.1 locus on blood DNA isolated from HNPCC samples FT (11, 93), 
EE(16, 93) and BeM a (14, 81). Am plisize/2.5Kb marker (M) bands are labelled as equivalent sizes in 
repeats. M ols = molecules. The 93 repeat allele of FT and EE is very unstable and biased toward 
expansions. The 81 repeat allele of BeMa is more stable but with an increased m utation rate com pared 
to the D M - 1 blood samples analysed at the same locus in Section 5.1.
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Figure 5.7 Preliminary SP-PCR at multiple trinucleotide repeat loci on HNPCC blood DNA sample
FT. Preliminary SP-PCR was carried out on HNPCC blood DNA sample FT at the DM-1, ERDA 1, SBMA 
and SCA1 loci. Am plisize/2.5Kb marker (M) bands are labelled as equivalent sizes in repeats. Mols = 
m olecules. Sizes of alleles at DM-1 and ERDAl  were determ ined by fluorescent PCR with GeneScan 
analysis and at SBMA and SCA1 by Kodak 1D Image analysis software. All loci are stable.
M 20 m ols /  reaction___________2 m ols /  reaction M
20 m ols /  reaction m  2 m ols /  reaction
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Figure 5.8 Preliminary SP-PCR at multiple trinucleotide repeat loci on HNPCC blood DNA sample
EE. Preliminary SP-PCR was carried out on HNPCC blood DNA sample EE at the DM-1, ERDA 1, SBMA 
and SCA1 loci. Am plisize/2.5Kb marker (M) bands are labelled as equivalent sizes in repeats. Mols = 
molecules. Sizes o f alleles at DM-1 and ERDAl were determ ined by fluorescent PCR with GeneScan 
analysis and at SBMA and SCA1 by Kodak ID Image analysis software. All loci are stable.
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Figure 5.10 Preliminary SP-PCR on HNPCC tumour DNA samples EE and BaF. Preliminary SP-PCR 
was carried out on HNPCC tumour DNA sample EE (16, 93) at the CTG 18.1 locus and BaF (10, 60) at the 
ERDAl locus. Am plisize/2.5Kb marker (M) bands are labelled as equivalent sizes in repeats. M ols = 
molecules. The lower allele of EE appears unstable but the upper allele could not be detected. Both alleles 
o f BaF seem stable at the ERDAl  locus, although artefacts can be observed between the two main PCR 
products.
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Figure 5.11 Second round fluorescent PCR on HNPCC tumour DNA. Second round fluorescent 
PCR at the CTG18.J locus on HNPCC tum our DNA sample EE (16, 93) and at the ERDAl locus on 
tum our DNA sample BF (10, 60). PCR products are blue, GS2500ROX standard is red. GS2500ROX 
standard marker bands are labelled as equivalent in repeats. The lower allele o f  EE is unstable al the 
CTG 18.1 locus in the tumour but the upper allele could not be detected. Both alleles o f BF are stable 
at the ERDAl  locus although the SP-PCR artefact is still evident.
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Figure 5.12 Preliminary SP-PCR at the ERDAl locus on blood DNA from HNPCC individuals.
Prelim inary SP-PCR at the ERDAl  locus on HNPCC blood DNA sam ples JC (21 ,62) and NS (10, 75). 
A m plisize/2.5K b m arker (M) bands are labelled as equivalent sizes in repeats. M ol = m olecules.Both 
sam ples are stable, although artefact products can be seen in sample NS.
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Figure 5.14 Preliminary SP-PCR at the CTG 18.1 and DM-1 loci on sperm DNA extracted before and 
after radiotherapy treatment. Preliminary SP-PCR was carried out on sperm DNA extracted before (XRT-K) 
and after (XRT-G) radiotherapy treatment on individual 1970 (11,31) CTG 18.1 (5, 34) DM-1. Am plisize/2.5Kb 
m arker (M) bands are labelled as equivalent sizes in repeats. M ols = m olecules. There are no obvious, 
gross size differences after radiotherapy treatment.
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Sample Locus Progenitor
Al le l e
Length
No. of 
reactions
m Total
mols
analysed
No .
mutants
mr A .I . e .
XRT-K
1970
CTG18.1 11 204/240 1.9 455 4 0.88 0.049
31 195/240 1.67 402 23 5.7 -0.102
XRT-G
1970
CTG18.1 11 148/239 0.97 231 1 0.4 -0.009
31 137/239 0.85 203 12 5.9 -0.078
XRT-K
1970
DM-1 5 81/90 2.3 207 0 0 0
35 68/90 1.41 127 74 58.3 0.725
XRT-G
1970
DM-1 5 79/96 1.73 166 0 0 0
35 78/96 1.67 161 84 52.2 0.348
Table 5.1 Single molecule analysis of sperm before and after radiotherapy treatment 
at the CTG18.1 and DM-1 loci. Sample XRT-1970 was typed to have (11, 31) CTG18.1 
and (5, 35) DM-1. XRT-K denotes before treatment, XRT-G denotes after treatment. 
Following first round SP-PCR, second round fluorescent PCR was carried out on the single 
molecule products. Positive reactions were scored according to Poisson analysis and the 
mutation rates and average length changes calculated.
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Figure 5.15 Allele distributions of the larger allele in sperm DNA from individual X R TI970 at the 
CTG18.1  and DM-1  loci before and after radiotherapy treatment. Second round fluorescent PCR 
products were analysed with GeneScan software and the frequencies o f the detected alleles plotted above, 
a denotes before and ■ denotes after radiotherapy treatment. There is a slight change in progenitor 
allele frequencies at the two loci, but probably due to stochastic variation in the samples.
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Chapter 6
Discussion
The initial aim of this project was to establish the natural behaviour of two trinucleotide repeat 
loci, both somatically and in the male germline, and then to observe how this behaviour could 
be adversely affected, if at all, by trans-acting factors such as mutations in mismatch repair 
genes, that would normally correct the repeat should any mutations occur. This was possible 
after the discovery of two expandable trinucleotide repeat loci known as CTG18.1 and ERDAl 
on chromosomes 18q21.1 (Breschel etal., 1997) and 17q21.3 (Nakamoto et a l, 1997) 
respectively. Locus CTG18.1 is an expandable trinucleotide repeat in the putative third intron 
of the SEF2-1 gene and was first identified in 1997 while searching for a candidate for 
Bipolar Affective Disorder (BPAD), although it was discounted as involved in the disorder. 
CTG18.1 demonstrated a heterozygosity of 84% with the capacity to achieve allele lengths of 
greater than 2,000 repeats. ERDAl was detected by the RED method and alleles up to 115 
repeats have been detected (Vincent et al, 1999). Other trinucleotide repeat loci that cause 
disease have expanded allele frequencies and hence incidence rates of 1 in 8,000 {DM-1) to 1 
in 10,000 {HD). The CTG18.1 and ERDAl loci have an increased frequency of expanded 
alleles (>50 repeats) of approximately 3% and 15% respectively. It was therefore expected 
that a significant number of expanded alleles would be found when screening a large set of 
samples. The bank of semen samples collected from the Western Infirmary allowed PCR 
typing protocols to be developed and exact allele frequencies to be determined for each locus. 
628 and 616 chromosomes from the semen samples were typed at the CTG18.1 and ERDAl 
loci respectively in order to select candidates for SP-PCR analysis which would encompass 
both normal (<50 repeats) and expanded alleles. Initially fluorescent nucleotides were used 
for the PCR reactions to be analysed by GeneScan 3.1, but these were replaced with 
fluorescent primers due to weak signals and obscuring of the product bands by 
unincorporated fluorescence. Alleles ranging from 10-91 repeats and 7-82 repeats were 
observed at the CTG18.1 and ERDAl loci respectively. Samples where only one allele was 
observed were checked to confirm homozygosity by PCR Southern blot, but no further alleles 
were detected. It is possible that very large alleles that may be present in the samples cannot 
be detected by PCR and so the true frequencies of the alleles could be altered slightly. This 
could be resolved by restriction enzyme digestion of the two loci followed by Southern blot 
analysis, thereby resolving any hugely expanded repeats.
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The observed allele ranges of 10-91 repeats at CTG18.1 and 7-82 repeats at ERDAl in this 
study matched the data published by Breschel et a l (1997), Ikeuchi et a l (1998), Nakamoto et 
al (1997) and Deka et al (1999) indicating that the PCR products were accurate without 
requiring sequencing of the repeats to confirm allele lengths. Similarly to the DM-1 locus, the 
most common allele is at approximately 30-35% frequency, although this is a 5 repeat at DM- 
1, a l l  repeat at CTG18.1 and a 10 repeat at ERDAL The distribution of the alleles at ERDAl 
indicated this locus to be more stable than the CTG18.1 locus, which in turn is more stable 
than the DM-1 locus (Appendix 2). It has been well documented that alleles greater than 50 
repeats rapidly expand within one generation at the DM-1 locus, whereas similarly sized 
alleles are much more stable at CTG18.1 (Breschel et a l, 1997) and ERDAl (Nakamoto et a l, 
1997, Ikeuchi et al, 1998, Deka et al, 1999). This is reflected in the allele frequencies of 
repeats in this range, i.e. frequencies of alleles >50 repeats are 1 in 8000 at DM-1, 3% at 
CTG18.1 and 15% at ERDAL There is also a lack of alleles between approximately 40 and 
50 repeats which suggests that the larger alleles arose from rare large length changes from the 
smaller, normal alleles.
To confirm the observations from paternal transmissions at ERDAl of a bias toward 
contractions and providing data for the CTG18.1 locus, semen samples were selected 
primarily to analyse the range of 50-100 repeats, and this was extended to encompass normal 
sized alleles also. Large length changes could be assessed by analysing large quantities of 
DNA per SP-PCR reaction and expansions of 11 and 15 repeats from 35 and 38 repeat alleles 
at the CTG 18.1 locus, and a 25 repeat expansion from a 29 repeat allele at the ERDAl locus 
confirms that large increases in repeat length could give rise to novel expanded alleles in the 
population. To analyse small length changes, SP-PCR at the single molecule level underwent 
a second round of fluorescent PCR, then analysed by GeneScan 3.1 software. The advantage 
of combining two PCR techniques that allows separation of effectively single molecules and 
then precise sizing of the repeats enables an exact measurement to be taken of the numbers of 
DNA molecules (sperm) with alleles different to the progenitor, and hence mutation rates and 
average length changes could be calculated. In order to assess approximately the same 
number of molecules for each allele, a Poisson analysis was applied to the numbers of 
observed negative reactions in multiple PCR reactions and hence the amount of input DNA 
could be calculated. Blood DNA was not available from the semen donors and hence the 
progenitor allele in each case was determined by carrying out fluorescent PCR on the somatic 
DNA fraction and analysing the products with GeneScan 3.1. The single molecule data 
confirmed that in accordance with other trinucleotide repeats, there is an increasing mutation 
rate with increasing allele length at both loci. Single molecule observations for DM-1 
(Appendix 2), HD (Leeflang et al, 1995, Leeflang et al, 1999), SCA1 (Koefoed et a l, 1998), 
DRPLA (Takiyama et a l, 1999), and MJD/SCA3 (Takiyama et a l, 1997) in the male germline
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suggest that CTG 18.1 and ERDAl are much more stable and they have a mutation pattern 
similar to MJD/SCA3. MJD/SCA3 demonstrates an increasing frequency of contractions with 
increasing allele length, as do both CTG18.1 and ERDAl, although CTG18.1 seems slightly 
more varied. These differences may become less significant if a greater number of samples 
were analysed, but if not, they could be attributed to various haplotypes in the flanking 
sequence or variants in other genes that could be having an effect. Utilising PCR primers that 
specifically amplify ERDAl repeats with either the A or C polymorphism confirmed that 
alleles <50 repeats possessed the A variant whereas the larger repeats possessed the C variant. 
This suggests that if changes in the polymorphism predispose a repeat to increase in size, it 
was not detected here. This therefore suggests that the bimodal distribution of small and large 
alleles at the ERDAl locus reflects two sets of independent alleles derived from a small allele 
that possibly mutated immediately 3’ to the repeat and subsequently underwent a large 
expansion. This is strengthened further by the typing of the A/C polymorphism in 
chimpanzee DNA which found small repeats, all associated with the A variant. Although 
further typing would be needed of Gorilla and Orang-utan DNA to confirm that this is the 
ancestral haplotype, it seems likely that the ERDAl alleles are derived from a small repeat with 
the A allele, one of which underwent a mutation immediately 3’ to the repeat to the C variant, 
which could have predisposed it to expansion and hence establish the pool of large alleles.
It is also interesting that there is a sudden increase in the mutation rate between 35 and 40 
repeats at the CTG18.1 locus that is similar to that seen at the DM-1 (Appendix 2) and HD 
(Leeflang et a l , 1995, Chong et a l , 1997, Leeflang et a l , 1999) loci. Sample GS130 (31,40) 
shows a huge difference in mutation rate of 4.2% to 23.7% between the two alleles although 
there are only 9 repeats between them and subject to the same trans-acting factors within the 
genome of that individual. Sample GS148 (28, 35) has mutation rates of 2.8 and 7.5% 
respectively. Therefore, similarly to the DM-1 locus where there is a large increase to 
mutation rates of 40 and 60% for 34 and 35 repeats from a 17% mutation rate at a 32 repeat 
allele, and the HD locus where 30, 36 and 38 repeats have mutation rates of 12, 53 and 92% 
(Leeflang et a l, 1995), the mid 30 repeat range seems to stimulate a dramatic increase in 
instability. It seems therefore that irrelevant of the repeat sequence, lengths of 30-40 repeats 
are a major factor in determining an increased mutation rate, suggesting that an increased 
number of secondary structures such as hairpins could form as noted with the DM-1 repeat 
(Pearson and Sinden, 1998). 50% of 35 repeat DNA was found to form slipped stranded 
DNA (S-DNA), whereby alternative structures are induced by the repeats. Alternatively, given 
the fact that a 35 repeat trinucleotide has the same length as an average Okazaki fragment, 
slippage could be occurring in replication, leading to alternative structures in the DNA. The 
larger the repeat, the greater the likelihood that initiation of Okazaki fragment synthesis occurs 
within the repeat tract.
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The mechanism of meiotic drive has been hypothesised to contribute toward unequal numbers 
of affected offspring in DRPLA, MJD/SCA3 (Ikeuchi et al., 1996) and disputed in DM-1 
(Carey et a l, 1994, Gennarelli et a l, 1994, Hurst et al, 1995, Leeflang et a l, 1996). 
Comparing numbers of positive PCR reactions between upper and lower alleles in each 
individual at both loci using a Chi-squared test at a 95% confidence interval found no 
significant difference in the numbers of sperm with either allele. Therefore in the male 
germline, there is no evidence for meiotic drive in favour of either allele at each locus and 
hence segregation distortion could be the result of meiotic drive in females. However, in 
testing meiotic drive in the male germline, we are asking if there is a bias in the number of 
sperm with expanded trinucleotides compared to normal alleles. This does not reveal whether 
an expanded allele would confer some advantage on the sperm in fertilising an egg, i.e. 
motility and overall ability to survive for a longer period.
The behaviour of normal and expanded repeats at the CTG18.1 and ERDAl loci have now 
been established in the male germline. However, in order to assess how these repeats could 
change in response to defective mismatch repair, it was important to establish the level of 
mutations observed in somatic tissue. Therefore, blood DNA available from DM-1 patients 
were typed at CTG 18.1 and ERDAl and preliminary SP-PCR carried out at the CTG18.1 
locus on expanded alleles. As expected from SP-PCR at the DM-1 locus on blood DNA 
(Monckton et a l, 1995, Martorell et a l, 1998), the male germline is more unstable than the 
blood. Alleles up to 69 repeats at CTG18.1 were very stable and an 89 repeat allele is 
mutating but at a lower rate than would be expected at the DM-1 locus. However, similarly to 
the DM-1 locus, these mutations are biased toward expansions, thereby forming a definite 
lower boundary at the progenitor allele. The opposite could be said for the CEPH 
lymphoblastoid cell line DNA however, as SP-PCR at the CTG18.1 locus demonstrated how 
very large expansions up to 330 repeats have a definite upper boundary and display 
contractions in repeat length as far as the normal range. Other publications of expanded 
repeat behaviour in EB V transformed lymphoblastoid cell lines also show the same behaviour 
(Ashizawa et a l, 1996), suggesting this is a feature of how repeat sequences behave in 
transformed cell lines. The difference between the DM-1 and CTG18.1 repeats is that there 
are some expansions seen in the cell lines from the DM-1 repeat, but none detected in this 
example at the CTG 18.1 repeat. Therefore it seems as they are identical in the repeat 
sequence, the flanking DNA would be contributing to the type of instability observed. 
Observations in primary cell lines derived from the dura mater of a DM foetus found an 
increase in the size of the DM-1 repeat over time (Wohrle et al., 1995) and similarly in a 
transgene of approximately 160 DM-1 repeats in primary cell lines derived from transgenic 
mouse tissues (Pereira and Monckton, unpublished).
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Various cell line, blood and ovarian tumour DNA was available initially to investigate the 
possibility of microsatellite instability at the two loci under investigation. The parental cell 
line, A2780 was proficient in the MMR genes and hMLHl deficient derivatives were 
established by continuous exposure to cisplatin and selection for resistance (Anthoney et a l , 
1996). Typing at both loci and DM-1 uncovered instability of a 27 repeat at the CTG18.1 
locus from A2780 to the cell lines deficient in hMLHl and hPMS2. Comparison of blood 
and ovarian tumour DNA did not uncover any differences due to inability to resolve the 
repeats in the tumour sample. However, preliminary SP-PCR of ovarian tumour OT481 
discovered gross instability of a 106 repeat allele at the CTG18.1 locus with a bias toward 
expansions. It would have been very useful to analyse the blood DNA in this individual to 
help understand the behaviour of a 106 repeat in normal tissue, but unfortunately it was not 
available. It is assumed therefore a deficiency in the mismatch repair system is producing a 
RER+ phenotype detected as microsatellite instability.
To understand how expanded alleles at CTG18.1 and ERDAl would behave in tissues where 
we know the exact status of mismatch repair, blood DNA was first obtained from HNPCC 
individuals that had been investigated for mutations in hMLHl or hMSH2. These samples 
were further supplemented by a second set of blood samples from HNPCC individuals who 
were also confirmed to have MMR mutations, but the precise details are not available. PCR 
allele typing at CTG 18.1 and ERDAl uncovered two blood samples from individuals who 
were first degree relatives with a CTG18.1 expanded allele. A PCR Southern blot indicated 
that this large repeat was highly unstable which was subsequently confirmed with SP-PCR. 
This result was surprising as it was expected that the allele would be relatively stable in the 
normal tissue and potentially unstable in response to a complete deficiency in hMLHl in the 
tumour. Tumour DNA from one of the individuals, EE, proved inconclusive in that the upper 
allele did not resolve and the lower allele was unstable, but the amount of DNA was so low 
that it was not possible to have more than 1-2 molecules per SP-PCR reaction. It is likely that 
the DNA was damaged when the tumour was fixed in a paraffin block, although the upper 
allele may have expanded outside the limits of detection by PCR. A possible explanation for 
the phenomenon being observed in these individuals is that the hMLHl mutation is exerting a 
dominant negative effect on the wild type allele or on its partners in the mismatch repair 
complex and hence there is a vastly reduced function for this pathway. To exclude other 
possibilities such as inherited haplotypes in the family or that this is the normal behaviour for 
a 93 repeat, many more blood samples from normal individuals outside the family would have 
to be screened for CTG18.1 expanded alleles to compare. Given that a 106 repeat in OT481 
had a reduced instability compared to EE and FT for approximately an equivalent number of 
molecules per reaction, it is unlikely that this instability is the natural behaviour of a 93 repeat 
allele. It would also be interesting to investigate if other genes could be affected by the large
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expansions at CTG18.1 observed in OT481, EE and FT. The prime candidate would be 
SEF2-1, but also genes known to be involved in tumour etiology such as BCL-2 at 18q21.3, 
which is close to CTG 18.1.
Expanded alleles at the ERDAl locus were also investigated in the blood and tumour DNA of 
HNPCC individuals, but alleles up to 75 repeats in blood and 60 repeats in tumour were 
stable. Again, this demonstrates how stable this locus is although it has the same sequence of 
repeat as DM-1, CTG18.1, DRPLA, HD, MJD/SCA3, SBMA, and the spinocerebellar ataxias.
Finally, sperm DNA samples were available to answer the question of whether microsatellites 
could be sensitive to the effects of ionising radiation. The largest alleles detected at CTG18.1 
and DM-1 were from sample XRT-1970. Single sperm analysis of these repeats found no 
difference 65 days after treatment compared to before, and the results are more likely to 
confirm the accuracy of combining SP-PCR with fluorescent PCR. The mutation rates and 
average length changes were essentially the same and the slight differences are probably due 
to stochastic variation rather than a positive effect of the radiotherapy. Therefore this provides 
evidence that the effects of radiotherapy, if any, are subtle and should not dissuade parents 
from considering reproducing after treatment.
The aim of this project was to characterise the behaviour and mutability of two trinucleotide 
repeat loci with the same repeat sequence, but with different flanking DNA. Comparing the 
mutation rates and average length changes of these loci in the male germline demonstrated a 
clear effect of the influence of the flanking sequence. The ERDAl locus has low %GC 
content in the flanking sequence, whereas CTG18.1 has an increased %GC content. ERDAl 
is the most stable trinucleotide repeat loci yet characterised and CTG 18.1 is significantly more 
unstable, although not yet approaching that seen at DM-1. Suggestions are that the immediate 
flanking sequence of lOObp has a higher correlation of %GC content with instability than 
500bp, but no obvious conserved motifs have been found between the most unstable loci 
(Brock et al., 1999). The %GC content and the presence or absence of a CpG island could 
alter the conformational properties of the DNA or affect the methylation status which could in 
turn have an effect on DNA-binding proteins or the chromatin state of the DNA. Utilising the 
sensitive SP-PCR technique gives a clear insight into how the CTG 18.1 locus has responded 
dramatically to defects in mismatch repair, both in MMR deficient cell lines and HNPCC 
tissues, but also possibly in an ovarian tumour. This assay has also revealed a possible 
dominant negative mutation in the hMLHl gene which maintains its influence in two 
generations of a HNPCC family. In conclusion, we have successfully characterised the 
behaviour of two trinucleotide repeat loci and produced additional data to that arguing the 
significant effect of flanking DNA sequence on the stability of triplet repeats.
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Appendix One
CEPH DNA Samples
Sample CTG18.1 
Name
F-01 1332 11,11
M-02 1332 11,52
F-01 1334 17,25
M-02 1334 17,29
F-01 1344 11,11
M-02 1344 17,118
F-01 1420 15,330
M-02 1420 11,17
F-01 1424 11,26
M-02 1424 14,16
Radiotherapy Sperm DNA Samples
Sample
Name
CTG18.1 ERDA1 DM-1
1580 24,29 21,21 5,32
1699 11,11 10,21 5,5
1796 11,14 10,22 5,12
1840 11,17 14,65 5,13
1868 11,11 17,22 5,13
1969 11,29 10,52 12,29
1970 11,31 22,22 5,34
2038 14,14 10,22 13,14
2044 17,17 10,59 5,5
2048 11,17 16,23 5,5
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DM-1 Blood DNA
Sample
Name
CTG18.1 ERDA1
AJ 17,26 20,53
AS 11,14 11,20
AVM 14,25 20,56
CM 17,24 21,69
DF 14,32 10,20
DM 17,18 17,21
BA 1 7 10,17
JM 14,23 17,21
KW 11,28 17,19
MB 14,25 17,21
MJ 1 7 10,68
MS 11,26 10,19
MW 11,17 21,57
NJ 11,15 21,22
PaW 21,26 10,20
PeW 11,15 10,19
FG 14,22 10,20
RJ 11,15 22,61
FM 18,79 21,68
FB 11,14 20,21
SN 14,16 20
TB 17,22 1 0
TP 17,69 1 0
VW 17,54 10,21
WW 24,25 20
YM 11,72 10,21
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DM-1 patient blood DNA
Sample. CTG18.1 ERDA1
Name
101-3001 11,17 10,21
101-3004 11,17 21,69
101-3008 1 1 10,21
101-3056 15,69 10,22
101-3057 17,68 22
101-3059 11,15 10,22
101-3061 11,17 10,22
101-3065 15,17 22,59
101-3071 11,30 22,72
101-3080 11,30 21,68
101-3082 11,30 21,71
101-4001 1 1 10,22
101-4004 11,51 10,21
101-4010 1 1 10,22
101-4033 11,28 10,10
101-4035 11,28 10,10
101-4174 12,15 10,59
101-4177 11,69 10,22
101-4180 15,17 10,22
101-4184 14,15 10,22
101-4205 15,29 17,73
101-4221 11,17 21,62
101-4222 17,30 21,64
101-4223 11,17 21,61
101-5025 1 8 21,22
101-5053 11,28 10,62
114-1001 11,25 10,21
114-2005 25,34 20,21
114-3008 11,34 20,63
114-3673 11,25 21,21
119-2004 11,26 20,22
119-2005 1 7 20,22
119-3011 17,26 10,22
119-3017 17,25 17,22
125-2016 17,25 10,15
Sample CTG18.1 ERDA1
Name
125-3011 11,27 21,33
125-4014 11,17 21,23
137-1538 34,35 10,55
137-2004 15,35 22,54
137-2664 15,35 10,22
137-3666 1 5 10,21/22
152-2007 11,17 10,21
152-3021 27,89 21,21
152-3633 11,17 10,17
164-2009 1 1 10,21
164-3015 1 1 10,21
175-1001 11,25 10,22
175-2007 25,26 10,22
175-2009 17,25 10,17
175-2012 11,26 10,22
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Ovarian Tumours and Cell line DNA
Sample CTG18.1 ERDA1 DM-1
Name
LOVO 10, 13 10, 13 9, 17
AN3CA c 1 1 10, 20
A2780 11, 13 16, 27 10
MCP1 11, 13 16, 27 10
MCP2 11, 13 16, 28 10
MCP3 11, 13 16, 28 10
MCP5 11, 13 16, 26 10
MCP6 11, 13 16, 28 10
MCP7 11, 13 16, 27 10
MCP8 11, 13 16, 27 10
MCP9 11, 13 16, 28 10
OT437 11, 13 16 10
OT450 5 1 1 10, 21
OT481 5, 13 17, 106 21, 60
OT503 11, 13 1 6 1 0
POU478 10, 13 1 6 10
POWFLL 11, 29 15, 17 21, 27
DH 5, 13 1 1 21
\m 5, 19 11, 14 20
90 5, 13 1 4 10, 21
00 11, 13 17, 24 10, 21
PM 5, 13 12, 18 1 0
IM 14, 15 16 16
JC 10, 11 11, 14 10, 22
LD 5, 21 11, 30 10, 60
AC 5, 23 1 1 10, 21
PK 5, 11 11, 32 10, 53
LC 5, 26 11, 64 22, 51
MT 5, 12 14 10, 68
BH 5, 13 11, 24 10, 21
BD 11, 12 11, 26 52, 62
AM 1 3 21, 23 12, 19
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Chimpanzee DNA
Sample CTG18.1 ERDA1 DM-1
Name
FRITS 1 1 19, 22 22, 24
LOUISE 11, 12 19, 28 12, 19
/FFF 11, 12 19, 28 19, 22
MAANTEN 11, 12 19 19, 22
VANESSA 11, 12 22, 28 19, 24
DIANA 1 1 18, 19 15, 19
FLINT 1 1 19, 22 15, 24
DORIEN 1 1 19, 22 15, 22
SHERRY 11, 14 19, 26 20, 25
CLAUDETTE 1 1 19 22, 25
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HNPCC DNA
LabID Family Initials DM-1 CTG18.1 ERDA1
941713 hn5 MD
950068 hn1 VR
950863 hn9 FP
950864 hn9 BF
951675 hn9 BaF
951816 hn18 E
951855 hn18 FT
952156 hn26 JT
952505 hn32 IVP
960349 hn44 JC
964850 hn1 DR
965822 hn9 CP
968254 hn78 TJ
971614 hn86 NS
973409 hn100 GT
973411 hn83 CS
974845 hn83 PC
975563 hn5 PD
976171 hn110 RW
976478 hn5 ID
976563 hn112 ND
976652 hn114 PB
977229 hn117 BB
977510 hn119 ED
977576 hn100 KT
979006 hn131 CJ
979325 hn134 9C
986739 hn136 DC
986742 hn112 WC
986743 hn112 SS
986750 hn112 ND
988279 hn134 AC
992777 hn112 AA
9604517 hn1 TS
9702797 hn110 BW
hn18 GF
5,12 11,17 16 21
20,23 11,25 22 53
12,13 11,17 16 19
5,12 1 7 10 60
5,12 16,17 10 60
5,11 16, 93 21 22
5,11 11, 93 10 22
5 11,24 17 66
15,22 1 1 10 22
12,13 1 7 21 62
5,23 25,38 20 21
12 11,22 16 17
5 1 7 10 86
5,11 11,31 10 75
13 1 1 10 17
13,14 1 1 10 17
5,14 11,14 21 22
12,24 11,17 21 22
5,8 17,54 10 17
12,24 18 21 57
8,16 18,25 17
5,11 14,17 10 77
12 15,25 23 58
12,23 1 1 21 22
5,13 11,14 21 55
5,12 14,17 21 68
1 1 15,17 20 68
5,12 11,24 1 0
13,22 11,15 1 7
8,13 14,18 10 17
8,11 14,25 17 22
11,13 1 5 10 20
13,15 11,15 1 7
10 22
16,55
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HNPCC DNA
LabID Family Initials CTG18.1 ERDA1
000/021 1 21 1 BB 17 19,21
13 /3173 3173 BeMa 14,81 1 0
0 4 6 /3 0 6 9 3069 BeMc 11,46 10,16
2 2 /3 1 7 4 3174 BrM 1 1 10,15
0 3 1 /3 0 6 2 3062 BV 17,24 7,20
14 /3038 3038 CB 17,26 20,21
0 2 1 /3 0 0 7 3007 CF 11,14 21,59
/3 0 9 6 3096 0G 1 1 10,21
0 0 8 /3 1 6 6 3166 CK 14,15 10,19
0 3 6 /3 2 0 2 3202 CL 11,32 1 0
0 2 0 /3 1 7 3 3173 CR 14,17 10
0 1 5 /3 0 6 9 3069 ON 1 1 16,21
0 8 0 /3 0 6 2 3062 DA 11,14 20
0 0 0 /0 2 7 6 276 DR 11,24 10,20
0 1 2 /3 0 6 5 3065 DT 11,15 15,67
2 9 /3 0 6 2 3062 EA 11,17 10,22
0 0 0 /3 2 0 2 3202 FP 11,25 10,16
0 0 0 /0 1 5 5 155 GA 11,17 10,16
00 0 /5 4 0 540 JaM 25,27 10,14
/ 3 1 48 3148 JC 15,27 1 0
0 1 4 /3 0 2 8 3028 JH 1 7 10,16
0 2 6 /4 6 9 469 JiM 11,16 10,58
136/3001 3001 JiW 13,15 10,19
2 1 /3 1 5 7 3157 JoW 11,17 1 0
080/301 1 301 1 JT 17,23 10,15
0 0 0 /5 3 4 534 KH 11,17 20,21
1 7 /3014 3014 KP 13,17 16,21
000/0321 321 LC 1 1 10,56
64/3001 3001 LG 13,24 10,19
0 2 2 /3 2 0 2 3202 LM 17,25 10,17
014/301 1 3011 LT 17,23 10,16
0 7 7 /3 0 6 2 3062 MA 22,23 20
0 2 2 /3 0 3 3 3033 IVM 11,17 28,59
13 /3116 3116 MS 14,17 20,22
0 0 0 /3 1 0 7 3107 MT 17,27 20
4 1 /3 0 3 2 3032 NW 14,29 1 6
001/3011 301 1 OL 11,23 15,16
0 0 4 /3 0 8 4 3084 FP 11,17 21,51
HNPCC DNA
LabID Family Initials CTG18.1 ERDA1
000/3151  3151 FR 11 10
0 0 0 /3 1 9 0  3190  FC 11,17 10,38
0 1 0 /3 1 8 5  3185  FR 11,17 10
0 0 7 /3 0 9 5  3095 SE 14,17 10,20
0 3 3 /3 1 0 2  3102 SS 11,28 10,21
0 2 4 /3 0 3 2  3032 TW 17 14,61
145/3001 3001 VA 14,17 14,19
0 0 4 /3 1 2 7  3127  WC 14,35 10,16
01 1 /3032 3032 WW 11,22 20,61
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Semen DNA
Sample CTG18.1 ERDA1
Name
GS1 11,64 11,22
GS2
GS3 22,24 10,22
GS4 14,23 10,22
GS5 15,81 10,22
GS6 14,17 16,62
GS7 17,23 16,57
GS8 -
GS9 14,23 10,21
GS10 11,26 10,27
GS11 11,17 10,15
GS12 16,87 21,69
GS13 11,24 21
GS14 11,25 10
GS15 -
GS16 1 1 17,23
GS17 1 1,22 18,21
GS18 17,25 60,64
GS19 22,32 24,?
GS20 13,62 10,59
GS21 -
GS22 1 5 21,22
GS23 11,14 1 0
GS24 11,14 7,61
GS25 -
GS26 17,28 10,54
GS27 1 1 17,22
GS28 11,30 10,58
GS29 16,31 22,23
GS30 14,24 10,60
GS31 -
GS32 -
GS33 -
GS34 11,24 10
GS35 15,25 22,58
GS36 11,14 10,17
GS37 -
GS38 -
Sample
Name
CTG18.1 ERDA1
GS39 -
GS40 -
GS41 11,14 22,61
GS42 11,14 15,22
GS43 -
GS44 1 1 16,17
GS45 14,26 10,58
GS46 -
GS47 11,13 21,23
GS48 1 7 10,21
GS49 -
GS50 13,14 21,64
GS51 11,17 10,21
GS52 -
GS53 11,17 10,17
GS54 -
GS55 11,27 10,22
GS56 -
GS57 16,17 21,22
GS58 11,14 10,56
GS59 11,14 1 0
GS60 -
GS61 -
GS62 -
GS63 -
GS64 -
GS65 16,17 23,61
GS66 11,37 10,17
GS67
GS68
17,32 21,68
GS69 11,17 21,22
GS70 24,33 1 7
GS71 14,26 21,22
GS72 -
GS73 -
GS74 14,17 21,44
GS75 11,23 17,18
GS76 11,17 10,21
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Semen DNA
Sample CTG18.1 ERDA1
Name
GS77 14,60 10,21
GS78 11,31 15,63
GS79
GS80 1 1 10,59
GS81 25,26 57
GS82 14,21 17,60
GS83 11,24 1 0
GS84
GS85 11,30 10,58
GS86 1 1 21,22
GS87 17,25 10,55
GS88 1 1 10,57
GS89 11,14 10,21
GS90 11,23 10,16
GS91 11,14 10,15
GS92 11,16 10,22
GS93 11,33 17
GS94 11,14 10,36
GS95 14,25 21,22
GS96 13,14 10,21
GS97 11,26 1 7
GS98 1 1 10,72
GS99 11,17 10,21
GS100 16,22 1 7
GS101 1 2 21,60
GS102 16,24 21,22
GS103 11,25 10,56
GS104 11,20 10,22
GS105 11,30 18,21
GS106 14,17 17,70
GS107 11,21 17,58
GS108 14,17 10
GS109 14,24 1 0
GS110 11,17 10,74
GS111 14,28 10
GS112 1 7 10,22
GS113 11,17 10,21
GS114 15,17 10,22
Sample. CTG18.1 ERDA1
Name
GS115 11,26 16,60
GS116 11,21 10,21
GS117 11,25 10,52
GS118 17,24 10,58
GS119 11,25 10,17
GS120 1 4 18,21
GS121 1 7 18,21
GS122 11,17 18,21
GS123 14,16 187,21
GS124 17,67 -
GS125 11,15 18,21
GS126 14,24 -
GS127 11,17 1 07,21?
GS128 11,24 10,21
GS129 11,17 15,17
GS130 31,41 16,21
GS131 18,79 16,58
GS132 14 1 0
GS133 14,26 21
GS134 14 10,22
GS135 28,37 1 0
GS136 1 4 16,23
GS137 11,14 22
GS138 14,25 1 0
GS139 11,14 21,22
GS140 11,14 20
GS141
GS142 11,14 10,18
GS143 17,32 10,21
GS144 14 22,60
GS145 13,14 21,63
GS146 1 1 10,66
GS147 -
GS148 28,36 1 0
GS149 11,14 21,22
GS150 17,29 22
GS151 14,15 13,21
GS152 17,91 10,57
Semen DNA
Sample CTG18.1 ERDA1
Name
GS153 11,40 10,59
GS154 1 1 20,21
GS155 1 1 10,22
GS156 11,24 10,22
GS157 11,14 10,22
GS158 11,13 21,27
GS159 14,17 10
GS160 11,15 10,22
GS161 1 1 10,22
GS162 11,16 23,60
GS163 26,30 22
GS164 11,14 14,26
GS165 11,22 21,23
GS166 11,71 1 0
GS167 17,85 17,22
GS168 1 3 22,64
GS169 11,17 10,21
GS170 14,23 11,21
GS171 1 1 17,65
GS172 1 1 -
GS173 15,25 22,55
GS174 1 1 17,29
GS175 14,23 10,21
GS176 11,17 18,21
GS177 14,17 16,22
GS178 13,14 10
GS179 11,16 10,19
GS180 14,29 21,22
GS181 11,24 21,?
GS182 22,25 21,22
GS183 15,26 10,61
GS184 1 1 22,57
GS185 1 1 21
GS186 19,23 10,21
GS187 11,14 10,21
GS188 20,22 10,26
GS189 1 1 10,53
GS190 11,17 17,58
Sample CTG18.1 ERDA1
Name
GS191 23,26 10,17
GS192 14,22 10,21
GS193 1 1 21
GS194 17
GS195 14,27 10,22
GS196 14,24 22,65
GS197 11,26 16,52
GS198 14,20 10
GS199 11,30 10,22
GS200 11,14 10,23
GS201 11,27 1 0?, 16?
GS202 24,25 10,22
GS203 11,25 53
GS204 11,17 21,27
GS205 11,28 10,23
GS206 14,17 16,17
GS207 1 1 23,62
GS208 11,14 1 9
GS209 14,21 1 0
GS210 11,14 17,21
GS211 14,15 10,63
GS212 11,15 10,21
GS213 17,32 21,22
GS214 11,17 10,22
GS215 15,20 10,21
GS216 1 1 22
GS217 11,14 10,69
GS218 10,16 22,23
GS219 18,22 15,64
GS220 17,22? 15?
GS221 11,17 16,22
GS222 1 1 17,22
GS223 11,12 21,22
GS224 11,29 10,21
GS225 16,17 10,20
GS226 11,14 10,15
GS227 1 1 22
GS228 1 6 10
Semen DNA
Sample CTG18.1 ERDA1
Name
GS229 11,14 1 0
GS230 17,? 50,58
GS231 16,23 10,22
GS232 11,14 10,66
GS233 11,14 10,66
GS234 24,28 10
GS235 15,24 21,72
GS236 11,17 23,71
GS237 1 1 10,22
GS238 1 7 10,60
GS239 11,14 10,18
GS240 11,17 21
GS241 14,17 17,21
GS242 11,17 10
GS243 11,25 10,22
GS244 11,14 15,17
GS245 1 1 16,59
GS246 1 1 21,22
GS247 11,16 10
GS248 14,17 16
GS249 11,15 21,58
GS250 1 7 16,20
GS251 17,25 21
GS252 15,26 9
GS253 11,24 10,22
GS254 1 1 17,21
GS255 11,17 10,15
GS256 1 1 22
GS257 17,36 10,16
GS258 14,25 10
GS259 1 4 17
GS260 16,31 66
GS261 11,84 10,22
GS262 11,14 10,22
GS263 11,15 21,27
GS264 14,17 10,60
GS265 11,24 21
GS266 17,24 17,68
Sample CTG18.1 ERDA1
Name
GS267 11,14 10,22
GS268 1 7 10,22
GS269 11,22 18,21
GS270 11,17 10,16
GS271 11,24 10,21
GS272 15,33 10,22
GS273 11,75 17,21
GS274 14,16 1 0
GS275 11,17 10,17
GS276 1 1 10,21
GS277 11,12 21,62
GS278 11,14 17,65
GS279 14,17 1 0
GS280 15,25 21,22
GS281 13,15 1 0
GS282 14,17 10,21
GS283 1 7 10,22
GS284 11,17 21,25
GS285 11,24 22
GS286 17,26 20,49
GS287 1 1 1 0
GS288 24,32 10,55
GS289 11,17 10,62
GS290 11,23 17,22
GS291 16,17 21,59
GS292 11,15 21,27
GS293 1 1 10,17
GS294 11,14 10,59
GS295 14,24 10,23
GS296 11,20 21,60
GS297 - 10,64
GS298 11,17 17,21
GS299 11,15 10,21
GS300 11,77 17,67
GS301 11,28 1 0
GS302 14,62 10,21
GS303 14,64 17,22
GS304 14,17 22,68
Semen DNA
Sample CTG18.1 ERDA1
Name
GS305 11,14 10
GS306 11,15 10,82
GS307 11,62 10,21
GS308 1 1 10,21
GS309 1 1 16,17
GS310 17,27 21,22
GS311 35,37 17,28
GS312 11,22 10,21
GS313 1 1 1 0
GS314 14,27 10,15
GS315 15,17 1 0
GS316 11,25 20
GS317 11,15 20,26
GS318 11,26 10,21
GS319 1 1 21
GS320 1 1 16,21
GS321 11,25 10,61
GS322 14,17 57,60
GS323 17,83 10,16
GS324 11,36 10,21
GS325 1 1 20
GS326 11,14 -
GS327 1 1 10,20
GS328 11,17 10,20
GS329 15,82 10,57
GS330 1 1 21
GS331 11,24 10
GS332 15,24 20,28
GS333 1 1 10,20
GS334 11,15 17,20
GS335 1 7 1 0
GS336 11,17 21,52
GS337 1 5 20,50
GS338 14,17 58,60
GS339 15,17 1 6
GS340 11,14 10,21
GS341 17,23 10,64
GS342 1 4 21
Sample CTG18.1 ERDA1 
Name
GS343 11,14 59
GS344 11,15 16,20
GS345 14 10,22
GS346 1 5 21,60
GS347 11,17 10
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Appendix Two
DM-1 Single Sperm data
A llele Av ALC A llele Av MR
5 0 5 0
6 6
7 7
8 0 8 0
9 9
10 10
11 11
12 0 12 0
13 13
14 0 14 0
15 15
16 16
17 17
18 18
19 19
20 20
21 0 21 0
22 0 22 0
23 0 23 0
24 -0.089 24 7.6
25 -0.0395 25 3.93
26 -0.032 26 4.8
27 -0.021 27 16.185
28 -0.035 28 12.75
29 -0.1925 29 14.3
30 0.007 30 15.64
31 31
32 -0.103 32 16.71
33 33
34 0.3805 34 37.55
35 0.581 35 58.2
36 36
37 37
38 38
39 39
40 40
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